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Interstitial lung diseases (ILDs) are fibrotic disorders with chronic inflammation and 
fibrinogenesis leading to lung scaring and lung function decline. Ultimately, 
progressive pulmonary fibrosis results in altered pulmonary physiology, abnormal gas 
exchange, and organ failure. ILDs include known causes and idiopathic causes, as it 
is the case of idiopathic pulmonary fibrosis (IPF) and non-specific interstitial 
pneumonia (NSIP). The most detrimental type of ILD is IPF in which anti-fibrotic 
drugs (nintedanib and pirfenidone) only decrease disease progression. For other ILD 
types, corticoid treatment helps to decrease exacerbation. Currently, clinical trials are 
evaluating the applicability of anti-fibrotic drugs for treating non-IPF ILDs. Therefore, 
mechanistic insights and in-depth cell characterization during tissue injury and 
remodeling in ILD are of great interest in the respiratory medical field. 
Circulating immune cell populations have been suggested to play a critical role in 
ILDs. For instance, mononuclear phagocytes are involved in the initiation, repair and 
regeneration of pulmonary fibrosis. Moreover, the close interaction between 
circulating and lung tissue-resident immune cells is critical to contribute to tissue 
homeostasis or lead to disease. However, precise myeloid phenotypes (e.g. myeloid-
derived suppressor cells and monocytes) and their mechanisms of recruitment in 
ILDs have not yet been explored. 
In the first results chapter of this thesis, myeloid-derived suppressor cells (MDSC) 
abundance and function were investigated for the first time in IPF patients. For that, 
peripheral blood of 170 patients including IPF, non-IPF ILD, chronic obstructive 
pulmonary diseases (COPD) and controls were collected to characterize and quantify 
MDSC by flow cytometry. Circulating MDSC in IPF and non-IPF ILD were increased 
when compared with control. Moreover, cross sectional and longitudinal analysis of 
the abundance of MDSC inversely correlated with pulmonary function test in IPF 
only. IPF patients with high number of MDSC showed downregulation of co-
stimulatory T cells signals quantified by qRT-PCR. Furthermore, MDSC were able to 
suppress lymphocytes CD4+ and CD8+ cells proliferation in vitro. Last, CD33 CD11b 
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double positive cells, suggestive of MDSC, were found in neighboring fibrotic niches 
of the IPF lungs. Taking together, these results show that MDSC are potential 
biomarker for IPF and are suppressing T cell responses. 
In the second results chapter, we aimed at analyzing monocyte phenotype and 
recruitment from the blood to the lung tissue in ILD. Importantly, CX3CR1 expression 
on immune cells has been demonstrated to increase fibrosis features. For that, flow 
cytometry analysis of circulating monocytes was performed in 105 subjects (83 ILD, 
and 22 controls). Monocyte localization and abundance in the lung was assessed by 
immunofluorescence and flow cytometry analysis. For receptor-ligand function and 
transmigration pattern, monocytes were isolated from blood and cultured either alone 
or with endothelial cells. Here, we showed that classical monocytes (CM) were 
increased, while non-classical monocytes (NCM) were decreased in ILD: NSIP, 
hypersensitivity pneumonitis (HP) and connective tissue disease associated with ILD 
(CTD-ILD) compared with controls. Monocytes abundance positively correlated with 
lung function. Fractalkine levels, the ligand of CX3CR1, were higher in lung tissue 
than in plasma in ILD and also co-localized with bronchial ciliated cells. Fractalkine 
enhanced endothelial transmigration of NCM in ILD only. Flow cytometry and 
immunofluorescence staining showed increased NCM in ILD. NCM-derived cells in 
the ILD lungs co-stained with CX3CR1, M2-like and phagocytic markers. In 
summary, we show that epithelial-derived fractalkine drives the migration of NCM-
CX3CR1 which provides an interstitial scavenger and phagocytic myeloid cells 
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1.1  Interstitial lung diseases 
Interstitial lung diseases (ILDs) are also called diffuse lung parenchymal diseases 
(DLPD) or pulmonary fibrosis (PF). According to the American Thoracic Society 
(ATS) and European Respiratory Society (ERS) statements, ILD/DPLD/PF describes 
a large group of lung parenchymal diseases characterized by multiple alterations in 
lung physiology (Travis et al., 2013). ILD patients show impaired gas exchange, 
excessive and progressive accumulation of extracellular matrix (ECM), as well as 
high influx of inflammatory cells (Travis et al., 2013).  
ILDs are categorized according to their cause (figure 1). The known causes of ILD 
are drug toxicity, connective tissue diseases, environmental exposures, and genetics. 
ILD with no previous cause or association are classified as idiopathic. ILD can also 
be classified as granulomatous diseases, in these cases patients display higher 
susceptibility to infections (Fischer & du Bois, 2012). 
 
Figure 1. ILD categorization is divided in four different groups according to etiology: 
1) known causes, 2) idiopathic, 3) granulomatous, 4) others  (adapted from (Fischer 
& du Bois, 2012)).  
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1.2  Epidemiology, complications and mortality in ILDs 
ILDs cases are internationally widespread. Idiopathic interstitial pneumonias (IIP) 
includes  idiopathic pulmonary fibrosis (IPF) which is the most common and harmful 
IIP (Cottin et al., 2019) (Raghu et al., 2011). However, other ILDs: non-specific 
interstitial pneumonia (NSIP).  hypersensitivity pneumonitis (HP), connective-tissue 
diseases (CTD) and Sarcoidosis have shown high complication and mortality risk due 
pulmonary fibrosis as well (Wells et al., 2018). 
 
1.2.1 Idiopathic ILDs 
Idiopathic interstitial pneumonias (IIP) are a classification of ILDs with unknown 
etiology, such as IPF and NSIP (Travis et al., 2013). IPF is the most detrimental type 
of ILD, with 3-5 years of median survival. Approximately 10-20% of IPF patients are 
admitted in hospitals with acute exacerbation per year. Most of the IPF patients with 
exacerbations die from acute respiratory failure. IPF cases have been reported to be 
more frequent in Europe and North America than South America and Asia (Raghu et 
al., 2018). In the United States, the prevalence of IPF is estimated to range from 10 
to 60 cases per 100,000 among adults over the age of 65 years old (Lederer & 
Martinez, 2018). In Europe, the incidence of IPF is increasing to rates around 3-9 per 
100,000 per year  (Hutchinson, Fogarty, Hubbard, & McKeever, 2015). IPF cases are 
more common in men than women (Ley & Collard, 2013). In contrary to IPF, most of 
the patients diagnosed with idiopathic fibrotic-NSIP are non-smokers and middle-
aged women and 46% of NSIP cases are reported in Asian countries. Moreover, 
NSIP survival rate is 82.3% after 5 years and 73.2% after 10 years.  (Travis et al., 
2008). 
 
1.2.2 Known causes of ILDs 
ILD is an important clinical manifestation in CTD. CTD-ILD includes scleroderma, 
rheumatoid arthritis, Sjögren’s syndrome and polymyositis/dermatomyositis. Cohorts 
from United States and Europe have shown that CTD-ILD is reported in 70% of the 
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scleroderma cases, 10-20% rheumatoid arthritis, 9-24% Sjögren’s syndrome and 20-
70% in myositis (S. C. Mathai & Danoff, 2016). The median survival of CTD-ILD 
patients (scleroderma and Sjörgren) is 5-8 years (Vij & Strek, 2013). Generally, CTD-
ILD is diagnosed in adults at age of 40 representing a worse prognosis than IPF 
when adjusted by age (Kocheril et al., 2005). 
 
1.2.3 Granulomatous ILDs 
HP incidence in the United States is more common in women who are 65 years old. 
The yearly prevalence rate of HP is approximately 11 per 100,000 adults (65 years 
old or older), in which 20-29% reported cases of HP-ILD. When HP is associated to 
ILD, mortality rate increases up to 10%. In 4 years (between 2004 and 2008), 
mortality rate of HP patients was 72% and HP-ILD was 80%. Thus, after 8 years 
following-up the same cohort, mortality rate was 58% for HP and 71% for HP-ILD. 
These data showed that older age and male gender were associated with higher 
mortality (Fernandez Perez et al., 2018). In Europe and South America (Brazil), HP is 
estimated to represent the most predominant ILD after IPF, with prevalence of 4 to 
15% and 15%, respectively  (Thomeer, Costabe, Rizzato, Poletti, & Demedts, 2001) 
(Riario Sforza & Marinou, 2017). Last, sarcoidosis has been observed mostly in 
young adults (men and women), 20 to 39 years old. In Europe, sarcoidosis incidence 
has been reported in 5 to 40 per 100,000 adults (Iannuzzi, Rybicki, & Teirstein, 
2007). Scandinavian countries are the greater contributors to Sarcoidosis cases in 
Europe. In Sweden, in 2003 till 2012, the yearly records of sarcoidosis cases are 
11.5 per 100,000 people (Arkema, Grunewald, Kullberg, Eklund, & Askling, 2016).  
 
1.3  Pathophysiology of ILDs 
The alterations in lung physiology that occurred in ILD are due to acute or chronic 
injuries from unique or continued exposures, which can be air-borne and blood-borne 
resulting in pulmonary fibrosis. The faster progression and detrimental 
pathophysiology of IPF resulted in more studies to characterize the disease.  
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Pathogenic mechanisms include cell-cell interactions of many different cell types, 
mainly epithelial cells, myofibroblasts, and immune cells (Bagnato & Harari, 2015). 
Furthermore, gene mutations and polymorphisms, microbiota, proteins interactions, 
and growth factors affect the lung epithelium and ECM (Wuyts et al., 2013). Animal 
and in vitro models, such as bleomycin, silica, asbestos and fluorescein 
isothiocyanate (FITC), TGF-b-induced fibrosis explore the pathophysiology of lung 
fibrosis (Q. Xu, Norman, Shrivastav, Lucio-Cazana, & Kopp, 2007) (Moore et al., 
2013).  
 
1.3.1 Idiopathic ILDs 
Molecular and cellular mechanisms are important regulators of disease status and 
progression in idiopathic ILDs. Indeed, IPF and NSIP are characterized by 
accumulation of fibroblasts and myofibroblasts differentiation, epithelial cells 
dysfunction, and immune cells dysregulation leading to ECM deposition (Ley, Brown, 
& Collard, 2014) (Fischer et al., 2015). 
The initiation of IPF is a result of excessive lung tissue repair in response to wound 
healing process (Thannickal, Zhou, Gaggar, & Duncan, 2014). Genetic changes can 
contribute to the development of IPF. For example, genetic variations in the telomere 
length, TERT, TERC, PARN, and RTEL1 are associated with an increased IPF risk 
(Armanios et al., 2007). Moreover, other gene polymorphism, as in MUC5B 
(rs35705950) closely related to IPF susceptibility (Seibold et al., 2011) (Peljto et al., 
2013). IPF patients with the MUC5B promoter polymorphism present a milder 
disease course, and improved survival (Seibold et al., 2011). IPF has also been 
shown to be associated with variations in DSK, AKAP13, CTNNA, and DPP9, genes 
related to cell adhesion and cell structure (Fingerlin et al., 2013) (Lederer & Martinez, 
2018). Importantly, MUC5B polymorphism has been shown to correlate with 
variations in DSK and AKAP13 (Allen et al., 2017).  
Injury factors, such as virus, cigarette smoke, exposure to radiation or drugs might be 
potential triggers to repetitive alveolar epithelial cell injury that leads to ECM 
deposition by myofibroblasts (Wuyts et al., 2013). In IPF lungs, alveolar type I (ATI) 
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and alveolar type II (ATII) cells are phenotypically altered. ATI and ATII apoptosis, 
stress and senescence lead to fibrotic scarring (Martinez et al., 2017). In IPF, 
hyperplasia of ATII cells and disruption of the alveolar epithelium within fibroblastic 
foci and loss of acinar architecture are important histopathology features of lung 
tissue damage (Gross & Hunninghake, 2001) (figure 2). Furthermore, IPF is 
characterized by increased bronchial basal cells and ATII migration and proliferation 
affecting tissue regenerative capacity. ATII apoptosis and senescence have been 
shown to contribute to increased secretion of pro-inflammatory cytokines, such as 
transforming growth factor beta (TGF-b), tumor necrosis factor alpha (TNF-α) and 
matrix metalloproteinases (including MMP-1, MMP-2, MMP-7, MMP-19) (Yu et al., 
2012) (Martinez et al., 2017). 
                     
Figure 2. IPF lung sections: hematoxylin-and-eosin (HE) staining of an open-lung 
biopsy specimen from a patient presenting with progressive dyspnea and diffuse 
parenchymal infiltrates. (A) Fibrosis in sub pleura indicated with black arrows, 
collapse and obliteration of alveolar air spaces. Magnification 15x. (B) Fibroblast 
focus indicated with asterisk and nodule of spindle cells arranging extracellular matrix 
deposition. Magnification 150x (adapted from (Gross & Hunninghake, 2001)). 
 
The injury of lung epithelium in IPF promotes migration, proliferation and activation of 
fibroblast and myofibroblast. Fibroblasts are activated by growth factors, such as 
fibroblast growth factor (FGF) and TGF-b that secrete ECM components increasing 
matrix stiffness (Wynn, 2008). IPF myofibroblasts are known to express and activate 
the levels of TGF-b by integrin pulling forces, increasing matrix stiffness. TGF-b 
expression has been shown to be an important regulator of pro-fibrotic surface 
markers (e.g PDGFRα, ROR1, SEMA7A) and transmembrane receptor (e.g. integrin 
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alpha (v) beta 6) in lung myofibroblasts (Heinzelmann et al., 2016) (Horan et al., 
2008). ECM in the lung is primarily consisted of collagen type I and IV, elastins and 
laminins (Booth et al., 2012). Additionally, fibronectin and glycosaminoglycans 
maintain lung cell polarity and survival (Booth et al., 2012). In this line, stiffer ECM 
and myofibroblast activation alter mechanical properties of the lung (White, 2015). 
Moreover, stiffer and pre-stained ECM, as well as, myofibroblast activation and ECM 
deposition leads to MMP secretion which in a feedback loop mechanism delays 
repair processes in IPF lungs (Parker et al., 2014). 
IPF pathophysiology is mediated by several alterations including the immune system. 
In IPF, the immune system contributes with a repetitive failure of pathogen response 
mechanisms which impact ECM deposition (Desai, Winkler, Minasyan, & Herzog, 
2018). T helper (e.g. Th2, Th17) cells promote fibrosis by suppressing the immune 
system and increasing myofibroblast proliferation (Barron & Wynn, 2011). Moreover, 
macrophages can enhance the production and secretion of pro-fibrotic mediators, 
such as TGF-ß and platelet-derived growth factor (PDGF) (Kolahian, Fernandez, 
Eickelberg, & Hartl, 2016). Neutrophils are known to produce MMP (i.e. MMP-9) 
(Ikezoe et al., 2014) and TGF-ß activating myofibroblast and promoting ECM 
deposition (Kolahian et al., 2016). Additionally, B cells accumulation have been 
shown to be associated with IPF manifestation and disease outcome (Xue et al., 
2013). 
Another form of idiopathic ILD is NSIP. NSIP may be idiopathic or secondary to 
toxins and CTD. NSIP pathophysiology is characterized by a constant infiltration of 
immune cells to the lung interstitium and lymphocytes to the alveolar space, as well 
as fibroblast within a variable collagen deposition (Jegal et al., 2005). NSIP pattern 
shows diffuse injury of the alveolar walls and parenchyma. However, different from 
IPF, NSIP fibrosis pattern is usually not distributed in the periphery (Smith, 2016) 
(figure 3). According to the histological features, NSIP can be divided in NSIP 
(inflammation and/or inflammation with fibrosis) and fibrotic-NSIP (mainly fibrosis) 
(Travis et al., 2013).  
Interstitial lung diseases 
_________________________________________________________________________________ 
   
 
27 
In NSIP, epithelial cell injury and repair failure, accumulation of fibroblast and 
myofibroblast differentiation, and dysregulation of immune cells in the lungs leads to 
collagen and ECM deposition (W. Xu et al., 2014). Different from IPF, NSIP does not 
have presence of fibroblast foci (Raghu et al., 2018). NSIP and IPF are both 
associated with variations in the telomere length TERT, TERC, and surfactant protein 
C (SFTPC) (Borie et al., 2016) (Nogee et al., 2001).  
 
 
Figure 3. Schematic representation of histopathologic differences in healthy, NSIP 
and IPF lungs: (A) represents a healthy lung with thin alveolar and pleura 
components; Bronchovascular bundles are located in the center of the lobules. (B) 
Represents a NSIP lung with increase of thickness in the parenchyma and alveolar 
walls thickening. Despite of a diffuse lung alteration (C) Fibrotic-NSIP lung shows the 
airway centered in the extracellular matrix deposition and scattered fibroblast foci. (D) 
IPF lung is represented by irregular fibrosis with complete disruption of alveolar walls 
and considered distribution of fibroblast foci (adapted from (Smith, 2016)). 
 
1.3.2 Known causes of ILDs 
Pulmonary fibrosis in CTD-ILD is characterized by a multi-compartmental disease 
manifestation with the presence of several concurrent impairment of lung function. 
The common underlying mechanisms of CTD-ILD in scleroderma, rheumatoid 
arthritis (RA), and Sjögren’s syndrome are immune-mediated lung damage (Fischer 
et al., 2015). 
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The scleroderma lung study shows that at the time of diagnosis there is no difference 
in dyspnea and lung function between cutaneous-limited and diffuse scleroderma 
patients. However, after 1 year, diffuse-scleroderma patients show increased HRCT-
scored fibrosis, worse functional activity and quality of life, when compared with 
cutaneous-limited scleroderma patients (Clements et al., 2007). In RA-ILD, the lung 
phenotype is characterized by inflammation of the pleura including pleura thickening 
and effusions, as well as epithelium and endothelium injury (Shaw, Collins, Ho, & 
Raghu, 2015). The Sjörgen’s syndrome-ILD manifestations include diffuse 
lymphocytic infiltration in the airways, bronchial hyperresponsiveness, bronchiectasis, 
bronchiolitis or recurrent respiratory infections (Flament et al., 2016). In general, the 
histopathology feature in CTD-ILD is represented by large lymphoid follicles 
surrounding the bronchiole similarly with NSIP pattern (Fischer et al., 2015). 
 
1.3.3 Granulomatous ILDs 
In HP, mononuclear cells (lymphocytes, monocytes and activated macrophages) 
infiltration to the alveolar and interstitium compartments is a characteristic disease 
pathophysiology feature (Salvaggio & deShazo, 1986). HP is characterized by 
antigen presentation and developed sensitization disease with humoral and cellular 
immune response (Bourke et al., 2001). In susceptible individuals, exposure to e.g. 
contaminated forced-air systems, birds (mainly budgerigar fanciers and pigeon 
fanciers), mold, dust, and occupational antigens result in HP. Genetic mutation in 
human leukocyte antigen (HLA) gene has been shown to contribute to the 
development of HP (Selman, Pardo, & King, 2012). Repetitive inflammation due to 
antigen presentation results in lung structure damage and fibrosis. In cases of 
chronic HP, the pathological hallmarks are the presence of center lobular fibrosis and 
peribronchiolar fibrosis, often associated with fibroblast foci which can mimic IPF 
(Salisbury et al., 2017).  
In sarcoidosis, the lungs are affected by a high infiltration of phagocytes and antigen 
presenting cells (APC) into the parenchyma and alveolar spaces. In sarcoidosis, HLA 
class II molecules and T cell receptors are important players during antigen and 
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bacterial infections. Along the same line, susceptibility to sarcoidosis may be a result 
of HLA polymorphism (Costabel & Hunninghake, 1999). Formation and accumulation 
of granulomas are fundamental abnormalities of sarcoidosis (Iannuzzi et al., 2007). 
The granuloma is a result of lymphocytes CD4+ cells mediating macrophage 
recruitment and activation (Rosen, 2007). Due to the lung injury differences, this 
thesis focuses in IPF, NSIP, HP and CTD-ILD. 
 
1.4  Clinical features of ILDs 
ILD patients present as first symptoms dyspnea and cough (often dry) that can be 
associated with fever, fatigue and weight loss. In IPF, it is common to present 
bibasilar inspiratory crackles and finger clubbing (Raghu et al., 2011). ILD are fibrotic 
diseases characterized by a restrictive alteration type in the pulmonary function test 
(PFT) (Alhamad, Lynch, & Martinez, 2001). Abnormal PFT in ILD are defined as 15% 
decline in the absolute values of diffuse lung capacity for carbon monoxide (DLCO), 
10% decline in forced vital capacity (FVC) and total lung capacity (TLC) (Raghu et 
al., 2011).  
Radiological approach gives a great support to the clinical diagnostics in ILD. Chest 
HRCT is crucial during ILD characterization depicting the reticular changes in the 
lung. The regions with low density, the so-called mosaic attenuation, are indicative of 
fibrosis (Martinez et al., 2017). The specific localization of tissue injury, bilateral, 
peripheral, basal distribution can be used to diagnose the precise type of ILD. 
However, HRCT does not always show a clear ILD pattern. In these cases, lung 
biopsy is required for a precise diagnosis and classification. Lung biopsy is a high 
risk procedure in which age, disease severity and comorbidities challenge its 
benefit/risk balance (Cottin, 2016). Therefore, less invasive procedures are greater 
contributors to investigate the molecular and cellular components involved in the 
pathophysiology.  
Molecular biomarkers and blood immunophenotyping help ILD management. 
Clinically, molecular biomarkers in ILD can elucidate disease predisposition, 
pathogenesis, mechanisms, as well as progression. Biomarkers are measured in 
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body fluids, such as blood/serum, and bronchoalveolar lavage (BAL). Molecular 
biomarkers show to be involved in different mechanisms of lung injury. Biomarkers 
related to the epithelial cell injury are surfactant proteins (especially SPC, and SPA2), 
Krebs von den Lungen-6 (KL6)/ mucin1 (MUC1), mucin 5B (MUC5B), telomerases 
(especially TERT and TERC) and cytokeratin 18 (cCK18) (Camelo, Dunmore, 
Sleeman, & Clarke, 2014). Biomarkers related to the immune dysregulation are toll-
like receptor 3 (TLR3), ELMO domain containing 2 (ELMOD2), toll-interacting protein 
(TOLLIP) and α-defenins (Ley et al., 2014). Importantly, specific biomarkers involved 
in the macrophage activation are CC chemokine ligand 18 (CCL18)/ PARC and 
YKL40 (Guiot, Moermans, Henket, Corhay, & Louis, 2017). Biomarkers of the 
adaptive immune system are represented by heat shock protein 70 (HSP70), CXC 
motif chemokine (CXCL13), T cells subsets and T regulatory cells (Tregs) (Sellares 
et al., 2018) (Vuga et al., 2014). Last, extracellular matrix deposition biomarkers are 
MMPs, phosphoprotein 1 (SSP1 or OPN), periostin and circulating fibrocytes (Ley et 
al., 2014). Although, all those biomarkers show to be associated with pulmonary 
fibrosis diagnosis, prognosis, and/or mortality, there is no clear available biomarker 
for clinical practice yet (Guiot et al., 2017). Importantly, the serum biomarkers: 
MMP7, SPD, CCL18 and KL6 are not recommended for distinguishing IPF from non-
IPF ILDs (Raghu et al., 2018). In a more comprehensive and integrated manner, 
systems medicine helps to characterize ILD, as well as to find and understand 
therapeutic approaches (Greiffo, Eickelberg, & Fernandez, 2017) (Appendix). High-
throughput omics technologies are an advantage tool to ILD. For instance, 
transcriptomics (i.e. MMP7) (Zuo et al., 2002) and genetics (i.e. MUC5B) (Seibold et 
al., 2011) studies show association with lung fibrosis progression and survival, 
respectively. 
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Figure 5. Systems medicine approaches applied to ILD: RNA, DNA, proteins, 
metabolites, microbiome and circulating cells are integrated in the omics 
technologies to future clinical applicability (Greiffo et al., 2017). 
 
1.5  Diagnosis of ILDs 
The diagnosis of ILDs starts with a comprehensive history, physical examination 
(especially chest auscultation, and detection of inspiratory crackles), physiological 
test (e.g. PFT) and laboratory tests. First, known causes of ILD are identified, such 
as  HP or CTD-ILD. HRCT helps to better identify the ILD-related patterns. In NSIP 
and HP, HRCT shows profuse nodules. In IPF, HRCT reveals characteristically 
reticular changes associated with traction bronchiectasis and honey combing. 
Honeycombing is defined as “sub pleural cystic airspaces with well-defined walls” 
(Raghu et al., 2018) (Martinez et al., 2017) (figure 4). When the HRCT is 
inconclusive, guidelines recommend open lung biopsy to help characterization of 
definitive patterns e.g. proliferative fibroblast and myofibroblast (fibroblast foci) in the 
lung parenchyma, distortion of the lung architecture and detection of honeycombing 
(Martinez et al., 2017) (figure 4). The histopathological patters of ILD are acute lung 
injury, fibrosis, cellular infiltrates, airspace filling, nodules, minimal changes (e.g. 
edema, pulmonary emboli, bronchiolitis) (Leslie, 2009).  
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Moreover, patient’s gender (G), age (A) and lung physiology (P) data (GAP index) 
can predict mortality of IPF patients. The GAP assessment has been developed as a 
prognostic estimation. GAP identifies three stages: 1 year mortality of 6% to stage 1, 
16% to stage 2 and 39% to stage 3 (Ley et al., 2012). 
 
Figure 4. Honeycombing revealed by HRCT and histology. (A) HRCT shows the lung 
lower zones and (B) sagittal plane of lungs from a woman diagnosed with IPF. Black 
and white arrows show honeycomb areas. (C) High-power H&E staining of IPF lung 
shows the micro-honeycombing areas indicated with black arrows (adapted from 
(Martinez et al., 2017)). 
 
1.6  Treatment for ILDs 
The treatment for ILDs is limited to ameliorate symptoms and minimize lung injury. In 
the past years, nintedanib and pirfenidone are recommended as anti-fibrotic drugs for 
IPF patients (Raghu et al., 2011). Both treatments show decrease disease 
progression by improving survival and declining FVC by approximately 50% over 1 
year of disease course (Raghu et al., 2011). The drug mechanism of nintedanib is 
designed to inhibit tyrosine kinase activity and of pirfenidone is designed to inhibit 
TGF-ß production. Nintedanib and pirfenidone have shown to decrease the number 
of respiratory exacerbations, hospitalizations and mortality rate of IPF (Richeldi et al., 
2014) (King et al., 2014). According to the latest guideline from the American 
Thoracic Society, European Respiratory Society, Japanese Respiratory Society and 
Latin American Thoracic Association (ATS/ERS/JRS/ALAT), IPF patients may not be 
treated with corticosteroids (i.e. prednisone), mucolytic drugs (i.e. N-acetyl cysteine), 
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anticoagulant medications (i.e. warfarin) and blood vessels constrictors (i.e. 
endothelin receptor antagonist, ambrisentan) because these drugs showed low 
confidence in the estimated anti-fibrotic effect for IPF patients (Raghu et al., 2015). 
Although pro-fibrotic therapies show to slow-down disease progression, the currently 
treatment of non-IPF ILD includes oral steroids (e.g. prednisone) and 
immunosuppressor (e.g. mycophenolate, azathioprine, cyclophosphamide) (Behr et 
al., 2017). The treatment of pulmonary fibrosis with oral steroid and/or 
immunosuppressor aims to decrease inflammation and suppress immune system 
over activity. However, in severe cases of ILDs those medicaments are not enough 
to control and decrease the disease progression (Raghu et al., 2011). Moreover, not 
all ILD patients respond to steroid treatments which show urgent need new strategies 
to treat non-IPF ILD (Behr et al., 2017). 
Furthermore, non-pharmacologic treatment has been strongly recommended in the 
clinical practice. In this line, oxygen therapy and pulmonary rehabilitation decrease 
dyspnea (Raghu et al., 2011) and improve exercise capacity, as well as patients’ 
quality of life (Dowman et al., 2017). Last, lung transplantation is recommended when 
patients in palliative treatment do not respond well and fibrosis is severe, however, 
median survival of lung transplantation is approximately 5 years (Chambers et al., 
2017). Altogether, more research towards treatment for ILD investigating molecular 
mechanisms or finding potential biomarkers is needed. 
 
1.7  Myeloid cells in ILDs 
Myeloid cells are originated from the hematopoietic stem cells niche and classified as 
common myeloid progenitor cells. Monocytes, macrophages, granulocytes, and 
myeloid-derived suppressor cells (MDSC) are originated from myeloid progenitor 
cells niche. Myeloid cells play an important role in organism protection under 
pathological conditions. Under homeostasis, myeloid cells are crucial in the initiation, 
perpetuation or inhibition of the adaptive immune system (Engblom, Pfirschke, & 
Pittet, 2016). 
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In pulmonary fibrosis, damage-associated molecules patterns (DAMP) are involved in 
tissue destruction and activation of myeloid and epithelial cells. DAMP signaling, 
such as TLR-2, IL-33, uric acid, ATP and TGF-ß, increase inflammation and fibrosis, 
as well as myeloid cells recruitment to the site of injury (Ellson, Dunmore, 
Hogaboam, Sleeman, & Murray, 2014). Simultaneously, blood clotting damages the 
vessels and affect tissue resident cells increasing the infiltration of myeloid cells to 
the lungs. In the inflammatory phase of ILD, monocytes and neutrophils phagocyte 
microorganisms and debris, and prevent the perpetuation of injury (Wynn, 2011). 
After this acute inflammatory phase, pro-repair cytokines (i.e. TGF-ß and IL-10) and 
M2-like macrophages activate myofibroblasts leading to ECM deposition and scar 
tissue formation (Wynn, 2011). Importantly, any dysregulation in the tissue 
regeneration phase can result in fibrosis. The repetitive damage process results in 
the accumulation of myeloid cells in the fibroblast foci and decreases the adaptive 
immune cell response, such as T cell activation and proliferation (Wynn, 2011) 
(Florez-Sampedro, Song, & Melgert, 2018). 
Myeloid cells display high plasticity which is induced by tissue environment. During 
ILD, myeloid derived cells are differentiated and activated in response to injury and 
surrounding matrix. Wound healing induces M2-like macrophages to increase the 
proliferation of fibroblasts-like cells (Bonnans, Chou, & Werb, 2014). Moreover, 
myeloid derived cells phenotype is critical to drive lung remodeling. Characterizing 
the immune cells phenotype is one step-forward to determine cell maturation and 
function in the site of injury (Tosh & Slack, 2002).  
 
1.7.1 Myeloid-derived suppressor cells (MDSC) in ILDs 
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of 
immature myeloid cells and leukocyte lineage (Talmadge & Gabrilovich, 2013). 
MDSC have two subsets, monocytic MDSC (M-MDSC) and granulocytic MDSC (G-
MDSC). MDSC are classified by negative expression of various myeloid origin cells 
including CD3, CD16, CD19, CD20 and CD56. M-MDSC are defined as Lineage- 
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HLA-DR- CD33+ CD11b+ and CD14+ cells, and G-MDSC as Lineage- HLA-DR- CD33+ 
CD11b+ CD66b+ cells (Talmadge & Gabrilovich, 2013) (Damuzzo et al., 2015).  
MDSC accumulation has been reported to be common in many chronic diseases and 
pathological conditions, such as lung cancer, transplantation, infection and 
autoimmunity (figure 6) (Gabrilovich & Nagaraj, 2009). For instance, in non-small cell 
lung cancer, patients with higher number of circulatory MDSC showed poorer survival 
or worse response to treatment (Feng et al., 2012). In chronic lung inflammation (i.e. 
tuberculosis (TB) and Pseudomonas aeruginosa infection) MDSC inhibited immune 
surveillance (du Plessis et al., 2013) (Rieber et al., 2013). Moreover, higher number 
of MDSC decreased numbers of Tregs and T cells in COPD patients (Kalathil et al., 
2014). It is known that MDSC function is linked to the suppressor capabilities and T 
cell response contributing to tumor-immune cell evasion (Talmadge & Gabrilovich, 
2013). 
 
Figure 6. MDSC origin and accumulation: (A) myeloid cells from the bone marrow, 
including immature cells, are mediated by granulocyte/macrophage colony-
stimulating factor (GM-CSF), macrophage CSF (M-CSF), stem-cell factor (SCF), 
interleukin-3 (IL-3) and FMS-related tyrosine kinase 3 (FLT3). (B) Acute and chronic 
infections, trauma, sepsis, and tumors promote the accumulation of immature cells, 
including MDSC (Gabrilovich & Nagaraj, 2009). 
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1.7.2 Monocytes in ILDs 
Monocytes are mononuclear leukocytes derived from the common myeloid progenitor 
niche. In the human and mouse blood, monocytes represent 10% of total cells, and 
5% of total leukocytes (Das et al., 2015). Human monocytes are classified in three 
different subsets, according to CD14 and CD16 expression: classical, intermediate, 
and non-classical. Classical monocytes are defined as CD14+++CD16+, intermediate 
monocytes as CD14+CD16+ and non-classical monocytes CD14+CD16++ (Ziegler-
Heitbrock, 2007). Classical monocytes account for approximately 85% of total 
monocytes. Intermediate and non-classical monocytes represent 5 and 10% of total 
monocytes, respectively (Passlick, Flieger, & Ziegler-Heitbrock, 1989). Mouse 
monocytes are classified in classical and non-classical, according to Ly6C 
expression. In mouse, classical monocytes are classified as Ly6Chigh and non-
classical monocytes Ly6Clow (Auffray et al., 2007). Moreover, in human and mouse 
classical monocytes are defined as CCR2hiCX3CR1low cells and non-classical 
monocytes as CCR2lowCX3CR1hi cells (Shi & Pamer, 2011) (Auffray et al., 2007) 
(Ginhoux & Jung, 2014) (figure 7). 
The role of classical monocytes in humans and mice has been broadly explored 
whereas non-classical monocytes phenotype, function and recruitment are still 
unclear (Jung, 2018). As an illustration, cell tracing studies in mice showed that 
monocytes in injured tissues present a classical CCR2+ phenotype. In the tissue, 
classical CCR2+ monocytes contribute to inflammation and angiogenesis (Florez-
Sampedro et al., 2018). Furthermore, CCR2 is an important chemokine necessary for 
monocytes to exit the bone marrow as well supply peripheral monocyte pools (Patel 
et al., 2017) (Ginhoux & Jung, 2014) (Jung, 2018) (figure 7). The fates of classical 
monocytes after recruitment from the bone marrow are: 1) to migrate from blood to 
tissue or 2) remain in the blood and differentiate into intermediate monocytes and 
later non-classical monocytes (Patel et al., 2017).  
The role of non-classical monocytes in mice has been described as resident and 
patrolling cell because they regulate and remain in the vascular system (Geissmann, 
Jung, & Littman, 2003). However, there is no substantial evidence that the same 
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phenotype and function occur in humans (Narasimhan, Marcovecchio, Hamers, & 
Hedrick, 2019). Non-classical monocytes in humans and mice are characterized by 
high expression of CX3CR1. The unique ligand of CX3CR1 is fractalkine (CX3CL1) 
which is known for regulating monocytes survival (D'Haese, Demir, Friess, & Ceyhan, 
2010; Landsman et al., 2009). For example, in liver fibrosis mouse model non-
classical CX3CR1+ monocytes might supply tissue macrophage pools, and regulate 
immune responses to injury and infection via M2 differentiation, contributing to 
regression of fibrosis (Ishida, Gao, & Murphy, 2008) (Brempelis & Crispe, 2016). In 
kidney fibrosis non-classical monocytes CX3CR1+ cells induce generation of reactive 
oxygen species (ROS), and production of fibrotic mediators, as TGF-b and collagen-I, 
perpetuating fibrosis (Hochheiser et al., 2013) (Shimizu et al., 2011). In airway 
inflammation, CX3CR1 axis has been described to increase immune cells influx 
(Mionnet et al., 2010). Overall, the role of CX3CR1-fractalkine axis is shaped by 
every specific tissue and environment. 
 
 
Figure 7. The phenotype of mouse monocyte: (A) monocytes are originated in the 
bone marrow from the hematopoietic stem cells (HSC) mediated macrophage and 
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dendritic cell (DC) precursor (MDP) and common monocyte progenitor (cMoP). (B)  
Circulatory classical (Ly6Chi) and non-classical (Ly6Clow) show different phenotype 
and function. (C) Classical monocytes are rapidly recruited to sites of inflammation 
where non-classical monocytes patrol the luminal surface of endothelial cells. The 
precise role of non-classical monocytes under pathological conditions is still unclear. 
CSF1R (colony-stimulating factor 1 receptor), GMP (granulocyte–macrophage 
progenitor) (Ginhoux & Jung, 2014) last update (Jung, 2018). 
Non-classical monocytes adhesion and migration are mediated by fractalkine-
CX3CR1 binding (Jung, 2018). Recently, it has been shown that increased levels of 
fractalkine in the lung of scleroderma and patients were associated with ILD 
progression (Hoffmann-Vold et al., 2018). Additionally, non-classical monocytes 
participate in RA initiation and progression (Misharin et al., 2014) and showed 
increased migration from peripheral blood to synovial inflamed tissue (Kawanaka et 
al., 2002). More recently, single cells RNA-sequencing identified in lung fibrosis 
mouse model a transitional population of monocyte-derived CX3CR1+ cells that were 
localized in the fibrotic niche and contributed to fibroblast accumulation (Aran et al., 
2019). However, the mechanisms involved in non-classical monocyte phenotype and 
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2. Objectives  
 
Immune system dysregulation has gained important attention in ILD field. Due to 
deep investigation in characterizing the innate immune cells and their contribution to 
pulmonary fibrosis pathophysiology we have opened an interesting topic not yet 
explored: the phenotype of MDSC and monocytes subsets in ILD. This thesis aims to 
characterize the myeloid immune cells abundance, recruitment mechanisms and 
their function  in ILD patients. 
To study the comprehensive immunophenotype of MDSC in IPF patients, here was 
aimed: 1) to quantify circulating MDSC in the peripheral blood and lungs tissue-
resident; 2) to investigate MDSC as potential biomarker; and 3) to assess the 
function of MDSC in the immune network. 
To study the comprehensive immunophenotype and cell recruitment mechanism of 
monocytes subsets in ILDs, here was aimed: 1) to quantify monocytes subsets: 
classical, intermediate and non-classical in the peripheral blood and lung tissue; 2) to 
explore the functional markers expressed by monocytes subsets; 3) to depict the role 
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3. Material and Methods 
 
3.1  Subjects 
The study was performed in accordance with protocols approved by the Ludwig-
Maximilians Universität München ethics review board (numbers 180-14 and 454-12). 
All subjects provided written informed consent for the research study and molecular 
testing.  
Hundred-seventy subjects were included in the MDSC study. Of those, 69 subjects 
were diagnosed with IPF, 56 with non-IPF ILD (NSIP n=27, HP n= 17, CTD-ILD 
n=23), 23 with chronic obstructive pulmonary disease (COPD), and 22 were controls. 
To explore monocytes immunophenotype in ILD, 105 subjects were recruited. Of 
those, 36 were diagnosed with NSIP, 28 with HP, 19 with CTD-ILD, and 22 were 
controls.  
The diagnoses of ILD were performed by multidisciplinary consensus, based on the 
current ATS/ERS criteria (Travis et al., 2013). Control subjects did not have any 
signs of active infection, inflammation, and/or respiratory symptoms. 
 
3.2  Immune cells isolation and immunophenotyping by Flow Cytometry 
Fresh venous blood was collected in EDTA-coated vacutainer tubes (Sarstedt, 
Nümbrecht, Germany), peripheral blood mononuclear cells (PBMCs) were isolated 
by collection of buffy coats prepared by density gradient sedimentation 
(LymphoprepTM STEMCELL Technologies, Köln, Germany). Approximately, 18ml of 
blood was diluted in 10ml of phosphate buffer saline (PBS). Next, 12ml of 
Lymphoprep TM was slowly added to the diluted blood and centrifuged at 450x g, 
room temperature, minimum acceleration, no break, for 20 minutes. Thereafter, 
PBMCs fraction was collected. 
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For MDSC, 100µL of whole blood was stained with a cocktail of antibodies containing 
anti-human: Lineage (CD56, CD20, CD19 and CD16), HLA-DR, CD33, CD11b, 
CD14 and CD66b (Biolegend, San Diego, CA, USA) for 20 minutes at 4°C in the 
dark. For MDSC characterization, blood cells (lymphocytes, monocytes and 
granulocytes) were gated in Lineage- HLA-DR- CD33+ CD11b+. M-MDSC were 
defined as Lineage- HLA-DR- CD33+ CD11b+ CD14+ and G-MDSC as Lineage- HLA-
DR- CD33+ CD11b+ CD66b+. PBMCs were stained with CD3, CD4, CD8, CCR7, 
CD25 (Biolegend, San Diego, CA, USA), and FoxP3 (Becton Dickinson Bioscience, 
Heidelberg, Germany). In PBMCs, lymphocytes were distinguished as T cells (CD3+), 
T helper (Th) cells (CD3+CD4+): Th effector (CCR7-) and Th non-effector (CCR7+); T 
cytotoxic (CD3+CD8+): T cytotoxic effector (CCR7-) and T cytotoxic non-effector 
(CCR7+). Abnormal T cells were classified as: CD3+CD4+CD8+, suggestive Tregs 
CD4+CD25+ and Tregs as CD4+CD25+FoxP3+ (table 1). 
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Table 1. List of antibodies used for MDSC and lymphocytes analysis by flow 
cytometry: anti-human antibodies antigen, fluorophore, clone, manufacturer, and 
isotype. 
 
For monocytes subsets detection, PBMCs were stained with monocyte antibody mix 
containing anti-human: HLA-DR, CD14, CD16, CX3CR1, CCR2 (Biolegend, San 
Diego, CA, USA), and CD163 (Becton Dickinson Bioscience, Heidelberg, Germany) 
(table 2). Monocytes were gated in HLA-DR+ cells, followed by classification of 
classical monocytes (CD14+++CD16+), intermediate monocytes (CD14+CD16+), or 
non-classical monocytes (CD14+CD16++). Data are presented as % of total 
monocytes. Canonical markers CCR2, CX3CR1, and CD163 were analyzed in each 
subset of monocyte and data presented as mean fluorescence intensity (MFI) of total 
monocytes. 
Moreover, monocytes were detected in the whole lung cell suspension. For that, 
human explanted lungs or biopsies pieces of 1-2 mm2 were minced and incubated 
with 0.2% type II collagenase in DMEM medium containing 10% fetal bovine serum 
(FBS) for 2 hours on a roller at 37°C. Afterwards, lung pieces were meshed using a 
400-500 µm filter followed by a 100 µm filter. Cells were centrifuged 450g, 5 minutes 
at room temperature. Then, pellet was resuspended and cell number was detected 
by trypan blue staining and Neubauer chamber. Lung myeloid cells were isolated 
using the CD45 MicroBeads (Miltenyi Biotec; Bergisch Gladbach, Germany). CD45+ 
cells were stained with a mix of antibodies containing anti-human CD15, HLA-DR, 
CD14, CD16, MERKT, CD206 (table 2). 
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Table 2. List of antibodies used for monocytes analysis by flow cytometry: anti-
human antibodies antigen, fluorophore, clone, manufacturer, and isotype. 
 
Flow cytometry data acquisition was performed in a BD LSRII flow cytometer (Becton 
Dickinson, Heidelberg, Germany). For cell sorting, BD FACS ARIA II (Becton 
Dickinson, Heidelberg, Germany) was used. Data were analyzed using the FlowJo 
software (TreeStart Inc, Ashland, OR, USA). For setting up the gates, negative 
thresholds and isotype-labeled controls were used. 
 
3.3  Cell morphology characterization by cytospin 
Sorted M-MDSC and G-MDSC were used to perform cytospins. Approximately 1-3 x 
104 M-MDSC or G-MDSC were centrifuged at 250x g, at room temperature for 5 
minutes on cytospin microscope slides. Following the centrifugation, cytospin slides 
were stained with May-Grünwald-Giemsa dye used to determine the morphology of 
M-MDSC and G-MDSC. Moreover, cytospin slides were also performed for 
immunofluorescence staining. For that, slides of M-MDSC and G-MDSC were 
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stained with anti-human CD33 (catalog number HPA035832) and ITGAM (CD11b) 
(catalog number AMAb90911) (Atlas Antibodies-Sigma-Aldrich, St Louis, MO, USA). 
Antibodies were diluted in PBS + 5% BSA + 0.2% Tween, using the concentration of 
1:50, 1:250 and 1:2500, respectively. Next, 1:250 dilution of each secondary antibody 
Alexa Fluor 568 goat anti-rabbit, and Alexa Fluor 488 goat anti-mouse, respectively, 
was applied and incubated at room temperature (1 hour) in the darkness. Afterwards, 
slides were counterstained with DAPI (Sigma-Aldrich, St Louis, MO, USA) (1:2500) 
(1 minute) and cytospin slides were mounted with fluorescent mounting medium 
(Dako; Hamburg, Germany). Microscopy was performed using Axiovert II (Carl Zeiss 
AG; Oberkochen, Germany) and images were processed using ZEN 2010 software 
(Carl Zeiss AG). 
 
3.4  Lymphocytes suppression assay by co-culture of autologous MDSC and 
PBMC 
MDSC and PBMCs were isolated from the same subject for future co-culture. 
Approximately 5x106 PBMCs were stained with CFSE solution. Fresh CFSE solution 
was prepared using 5.625ml of PBS and 1µl of CFSE (CellTrace™, ThermoFisher 
Scientific, Eugene, OR, USA). PBMCs pellet was resuspended in 1ml of sterile PBS 
and 1ml of CFSE solution. Afterwards, stained-PBMCs were seeded alone or in co-
culture with autologous MDSC in a ratio of 1:4, respectively (3-5 wells, 96 wells 
plate). In both conditions, lymphocyte proliferation was stimulated adding 
Recombinant Human 100 U/mL IL-2 (BD Pharmingen, San Diego, CA, USA), and 1 
µg/mL OKT3 (CD3) (Biolegend, San Diego, CA, USA). Cells were kept in the 
incubator (37°C in humidified conditions containing 5% CO2) for four days. 
Thereafter, to characterize lymphocytes immunophenotype by flow cytometry, the 
cells were harvested and stained with anti-human: CD4 and CD8 (Biolegend, San 
Diego, CA, USA). CSFE fluorescence intensity of CD4+ and CD8+ cells was analyzed 
with flow cytometry (Alexa Fluor 488). The % of CFSE (indicative of cell proliferation) 
was analyzed between PBMC cultured alone or with MDSC. Data was analyzed with 
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FlowJo software (TreeStart Inc, Ashland, OR, USA). This protocol has been adapted 
from previous publications (Rieber et al., 2013) (Kostlin et al., 2014). 
 
3.5  IPF predictor genes expressed in PBMC by qRT-PCR 
Frozen PBMCs of IPF patients with high number of MDSC and controls were used 
for analysis of CD28, ICOS, ITK, and LCK (Table 3). First, RNA was extracted using 
RNeasy Mini Plus Kit (Quiagen, Venlo, Holland). Approximately 3-5x106 PBMCs 
were homogenized and lysed with 350µl of lysis buffer (Qiagen buffer RLT Plus) and 
transferred to the gDNA eliminator column placed in a 2ml collection tube followed by 
centrifugation (8000x g, room temperature, 30 seconds). Then, the flow-through 
solution was mixed with 350µl of 70% ethanol and transferred to RNeasy spin 
column placed in a 2ml collection tube followed by centrifugation (8000x g, room 
temperature, 15 seconds). The flow-through was discarded. Then, 700µl of buffer 
RW1 was added into the same column followed by centrifugation (8000x g, room 
temperature, 15 seconds). The flow-through was discarded. Then, 500µl of buffer 
RPE was added into the same column followed by centrifugation (8000x g, room 
temperature, 15 seconds). The flow-through was discarded. The previous step was 
repeated with 2 minutes of centrifugation. Then, the column was placed in a new 
collection tube and 30µl of RNase-free water was added into the column followed by 
centrifugation (8000x g, room temperature, one minute). The flow-through was 
collected for measuring mRNA concentration, using a NanoDropTM 1000 
spectrophotometer (NanoDrop Tech. Inc; Wilmington, DE, USA) at 260 nm. 
After obtaining mRNA, RNA denaturation and reverse transcription was performed. 
For denaturation, mRNA was exposed to a temperature of 70°C for 10 minutes (lid at 
75°C) (Eppendorf Mastercycler® pro, Germany). Thereafter, reverse transcription 
was performed using MuLV reverse transcriptase (Applied Biosystems, Carlsbad, 
CA, USA) and random hexamer primers (Applied Biosystems) and exposed to 20°C 
for 10 minutes, 43°C for 75 minutes, 99°C for 5 minutes finishing with long exposure 
to 4°C. The obtained cDNA was used for performing qRT-PCR. 
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For qRT-PCR a 96-well format for LightCycler® 480 DNA SYBR Green I Master 
(Roche; Penzberg, Germany) was used. For housekeeping gene and standardization 
of gene expression, we used GAPDH (Table 3).  
 
Table 3. List of genes used for IPF prediction by qRT-PCR: forward (FW) sequence 
and reverse (REV) sequence of GAPDH, CD28, ICOS, ITK, and LCK.  
 
3.6  MDSC and monocytes in the lungs by immunofluorescence 
Lung tissue sections from control (tissue tumor-free areas) and ILD subjects were 
used to localize and quantify myeloid cells: MDSC and monocytes subsets in the 
lung. 
Immunofluorescence staining was performed in lung tissue embedded in paraffin. For 
that, slides were deparaffinized by incubating overnight at 60°C, following by 
rehydration where slides were twice immersed in xylol (5 minutes, each), transferred 
to 100% ethanol (2 minutes, each), once in 90% ethanol (1 minute), 80% ethanol (1 
minute), 70% ethanol (1 minute), and finally flushed with distillated water (30 
seconds) to wash away the ethanol. Next, for antigen retrieval step slides were 
emerged in citrate buffer solution (pH 6.0) and placed into a Decloaking Chamber 
which was heated up at 125°C (30 seconds), 90°C (10 seconds), afterwards the 
slides slowly cooled down to room temperature. Then, slides were washed three 
times in Tris buffer, and blocked in 5% BSA – Tris buffer solution (1 hour) to prevent 
non-specific binding. Slides were placed in a wet chamber, primary antibodies were 
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added and slides were incubated at 4°C, overnight. The slides were rinsed three 
times with Tris buffer, and 1:250 dilution of each secondary antibody was applied and 
incubated at room temperature (1 hour) in the darkness. Slides were counterstained 
with DAPI (Sigma-Aldrich; St Louis, MO, USA) (1:2500) (1 minute). Once again, the 
slides were rinsed three times with Tris buffer, and covered with Fluorescence 
Mounting Medium (Dako, Hamburg, Germany). 
For MDSC detection in the lung, we used explanted lungs from controls lung section 
(n=3) and pulmonary fibrosis lung sections (n=3; IPF n=2, HP n=1) and previously 
recruited to measure the circulating MDSC. The slides were stained with anti-human 
CD33 (catalog number HPA035832) (1:50) and ITGAM (CD11b) (catalog number 
AMAb90911) (1:250) (Atlas Antibodies-Sigma-Aldrich, St Louis, MO, USA). Also, 
CD33 and α-SMA (catalog number A5228, Sigma-Aldrich, ST Louis, MO, USA) 
(1:1000) and CD11b and collagen type I (1:200) (600-401-103-0.1, Rockland, 
Oxfordshire, UK). Afterwards, 1:250 dilution of each secondary antibody was applied: 
Alexa Fluor 568 goat anti-rabbit, and Alexa Fluor 488 goat anti-mouse, respectively 
for CD33 and CD11b; Alexa Fluor 568 goat anti-rabbit, and Alexa Fluor 488 goat 
anti-mouse, respectively for CD33 and α-SMA; Alexa Fluor 568 goat anti-mouse, and 
Alexa Fluor 488 goat anti-rabbit, respectively for CD11b and collagen I. 
For monocyte subset detection in the lung, we used explanted lungs from four tumor-
free areas (controls) and six ILD patients (NSIP n=2, HP n=4). The slides were 
tripled-stained with anti-human von Willebrand Factor (ab11713), CD14 (ab181470) 
(Abcam, Cambridge, UK), CD14 (BAF383, R&D Systems, Abingdon, UK), CD16 
(ab109223, Abcam, Cambridge, UK), Fc gamma RIII/CD16 (NBP-42228, Novus 
Biologicals, Littleton, Colorado, USA) (CX3CR1 (ab8021, Abcam, Cambridge, UK), 
CD163 (NBP2-36494, Novus Biologicals, Littleton, Colorado, USA), CD68 (M0814, 
DAKO, Glostrup, DK), CX3CL1 (ab89229, Abcam, Cambridge, UK), acetylated 
tubulin (ab125356, Abcam, Cambridge, UK), collagen type I (600-401-103-0.1, 
Rockland, Oxfordshire, UK), and AXL (AF154SP, R&D Systems, Abingdon, UK). 
Primary antibodies were diluted using the antibody diluent (Zytomed Systems, Berlin, 
Germany), vWF (1:100), CD14 (1:100), and CD16 (1:200), CX3CR1 (1:500), and 
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CD163 (1:200), CD68 (1:50), CX3CL1 (1:100), acetylated tubulin (1:200), collagen 
type I (1:200), and AXL (1:200). 
Microscopy was performed using Axiovert II (Carl Zeiss AG; Oberkochen, Germany) 
and images were processed using ZEN 2010 software (Carl Zeiss AG). For 
quantification of monocytes, the number of as CD14+, and CD14+CD16+ cells (CD14 
red fluorophore, and CD16 green fluorophore) in the tissue was normalized as % of 
total cells (DAPI positive). Five pictures per slide were taken and double positive cells 
localized in the parenchyma and outside the vessel, stained for vWF (far red 
fluorophore), were quantified. 
 
3.7  Monocyte’s protein quantification by ELISA 
CC Chemokine Ligand 2 (CCL2) (catalog number DCP00) and fractalkine (CX3CL1) 
(catalog number DCX310) were used to quantify monocytes’ chemokines levels in 
plasma and tissue homogenate by enzyme-linked immunosorbent assay (ELISA) 
(Quantikine Kit R&D Systems, Abingdon, UK). First, for lung homogenate, human 
lung tissue was pulverized in liquid nitrogen and homogenized in one volume of lysis 
buffer (1M Tris HCl pF 7.5, 5M NaCl, 100% NP-40, 10% Sodium-deoxycholat, 0.1% 
SDS). Samples were subsequently centrifuged at 10,000g for 15 minutes at 4°C, and 
the supernatant was collected to measure protein levels by BCA Protein Assay Kit 
(Pierce, ThermoFisher, Rockford, IL, USA). Protein aliquots prepared with 100µg of 
lung were used to measure levels of CCL2, and 200µg were used to measure levels 
of fractalkine. For plasma, we used 1:1 (in Calibrator Diluent RD6Q) and neat 
samples for quantification of CCL2 and fractalkine, respectively. 
For CCL2, first 50µl of assay diluent RD1-83 diluent was added in each well. Then, 
200µl of prepared sample and standards (included in the kit) was added per well and 
incubated at room temperature for 2 hours. Samples were aspirated and wells were 
washed with Wash Buffer (the wash step was repeated 4 times). Next, 200μL of 
human-CCL2 conjugate was added to each well and incubated at room temperature 
for 1 hour. Human-CCL2 conjugate was aspirated from each well which was washed 
with Wash Buffer (the washing step was repeated 4 times). Afterwards, 200μL of 
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Substrate Solution was added to each well and incubated at room temperature for 30 
minutes. Finally, 50µL of Stop Solution was added in each well and the optical 
density was determined using a microplate reader set to 450nm, and wavelength 
correction of 540nm (Sunrise microplate reader, TECAN, Männedorf, Switzerland). 
CCL2 data was calculated by a generation of a four parameter logistic (4-PL) curve-
fit (GraphPad Prism, version 7.0, GraphPad Software, San Diego, CA, USA). All 
experiments were performed in technical duplicates. 
For fractalkine, first 100µl of RD1-88 assay diluent and 100µl of samples and 
standards (included in the kit) were added per well and incubated at 4°C for 3 hours. 
Then, samples were aspirated and wells were washed with Wash Buffer (the wash 
step was repeated 4 times). Next, 200µl of cold human-fractalkine conjugate was 
added in each well and incubated at 4°C for 1 hour. Afterwards, human-fractalkine 
conjugate was aspirated from each well following by washing with Wash Buffer (the 
wash step was repeated 4 times). 200μL of Substrate Solution to each well and 
incubated at room temperature for 30 minutes. Lastly, 50µL of Stop Solution was 
added in each well and the optical density was determined using a microplate reader 
set to 450nm, and wavelength correction of 540nm (Sunrise microplate reader, 
TECAN, Männedorf, Switzerland). Fractalkine data was calculated by a generation of 
a log/log curve-fit (GraphPad Prism, version 7.0, GraphPad Software, San Diego, 
CA, USA). All experiments were performed in technical duplicates. 
 
3.8  Monocyte subsets function by endothelial cell adhesion assay 
Immortalized murine endothelial cells (SVEC) were used to analyze monocyte 
adhesion. SVEC were cultivated and activated with TNF-α (10ng/mL) for 4 hours, at 
37°C in humidified conditions containing 5% CO2. Monocytes were isolated from 
PBMC using the Pan Monocyte Isolation Kit followed by CD16 MicroBeads (Miltenyi 
Biotec; Bergisch Gladbach, Germany), resulting in a separation of CD14+ and CD16+ 
monocytes. We performed a competitive assay where CD16+ monocytes ILD patient 
were labeled with green cell dye (LeukoTrackerTM, Cell Biolabs, INC.; San Diego, CA, 
USA), and CD16+ monocytes from control were labeled with red cell dye (Red Cell 
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TrackerTM Red CMTPX dye, Life Technologies; Carlsbad, CA, USA). CD16+ labeled 
monocytes were resuspended in two different conditions: 1) chemokine free (PBS 
2% FBS) and 3) fractalkine (PBS 2% FBS + 200ng/ml fractalkine) (Peprotech; Rocky 
Hill, NJ, USA) (figure 7). Subsequently, activated endothelial cells were co-cultured 
with freshly labeled CD16+ monocytes from control sample and CD16+ monocytes 
from ILD sample (1:1) for 15 minutes at 37°C in humidified conditions containing 5% 
CO2. Non-adherent cells were washed away, and adherent cells were fixed with 4% 
paraformaldehyde (PFA) for 15 minutes at room temperature. Adherent monocytes 
were imaged using a confocal microscope (LSM710, Carl Zeiss, 10x), and images 
were acquired by 6x6 tile scan, covering the whole surface area of each well. 
Adherent CD16+ monocytes were quantified using Imaris’ statistical analysis tool 
Software (Bitplane; version 8.1.2, Concord, MA, USA), where the total number of 
spot objects, representing the total number of cells were determined. This protocol 
has been adapted from previous publication (Gamrekelashvili et al., 2016). Data was 
normalized according to control (chemokine free), and adherent cells were defined by 
adhesion index (AI), as previously reported (Lo Buono et al., 2011). 
 
 
Figure 7. Monocytes adhesion assay: (A) CD16+ monocytes co-cultured with 
endothelial cells for 15 minutes. (B) CD16+ monocytes co-cultured with endothelial 
cells and fractalkine (CX3CL1) for 15 minutes. Non-adherent cells were washed 
away and adherent cells were fixed with 4% PFA. (C) CD16+ monocytes control were 
quantified using confocal microscopy (LSM710; Carl Zeiss). 
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3.9  Monocyte subsets function by chemotaxis migration assay 
Isolated monocytes seeded into a transwell (Corning® HTS Transwell® 96 wells 
permeable 5μM pore; Sigma-Aldrich; Kennebunk, ME, USA). To verify whether the 
migration of monocyte subsets responded to different stimuli, we had three different 
conditions in the lower chamber: chemokine free (RPMI 1640 + 0.5% BSA), 
fractalkine (RPMI 1640 + 0.5% BSA + 200ng/ml fractalkine) and fractalkine with 
antibody blocking fractalkine (RPMI 1640 + 0.5% BSA + 200ng/m fractalkine + 
200ng/m mAb-fractalkine) (figure 8). Monocytes were incubated at 37°C in humidified 
conditions containing 5% CO2 for 3 hours. Thereafter, migratory cells were harvested 
and stained with an antibody mix containing anti-human HLA-DR, CD14, and CD16 
followed by flow cytometry. Data acquisition was performed in a BD LSRII flow 
cytometer (Becton Dickinson, Heidelberg, Germany). Migratory monocytes data were 
analyzed using the FlowJo software (TreeStart Inc, Ashland, OR, USA). Negative 
thresholds for gating were set according to isotype-labeled controls. Data were 
normalized using control wells (chemokine free) as an indicator of conversion 




Figure 8. Monocytes migration assay: (A) Monocyte were isolated and added into a 
transwell (5µM pore membrane). (B) In the bottom of the transwell was added 
fractalkine (CX3CL1). (C) In the bottom of the transwell was added fractalkine 
(CX3CL1) together with monoclonal antibody blocking fractalkine (CX3CL1).  
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3.10 Statistical analysis 
Three and more group comparisons were analyzed using the one-way analysis of 
variance, with non-parametric Kruskal-Wallis test, followed by Dunn’s multiple 
comparison test. For, two group comparisons were analyzed non-parametric or 
paired Student t-test or Mann-Whitney test. Associations between variables were 
established using linear regression and Pearson correlation. Statistical analyses and 
significance was defined as p less than 0.05. 
For MDSC, results are presented as scatter dot plots with mean ± SD. Data was 
analyzed using GraphPad Prism (version 5.0, GraphPad Software; San Diego, CA, 
USA). For monocytes, results are presented as box and whiskers vertical graphs with 
mean ± standard deviation. Data was analyzed using GraphPad Prism (version 7.0, 
GraphPad Software; San Diego, CA, US 
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4.1  MDSC 
The MDSC work presented in this thesis has been published in the ERJ, 2016 
(PMID: 27587556); Fernandez I.E, Greiffo F.R, et al. (Fernandez et al., 2016) 
(Appendix). 
 
4.1.1 Patients demographics 
The cohort of the subjects in the immunophenotyping characterization of MDSC 
included patients diagnosed with IPF, non-IPF ILD (NSIP, HP and CTD-ILD), and 
COPD. Subjects without diagnose of chronic diseases and inflammation were 
included as controls (Table 3).  
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Table 3. Subjects demographics: data are presented as % and number of affected 
patients. Idiopathic pulmonary fibrosis (IPF); Non-specific interstitial pneumonia 
(NSIP); Hypersensitivity pneumonitis (HP); Connective-tissue diseases (CTD); 
Chronic obstructive pulmonary disease (COPD). Lung function data are presented as 
Mean±SD, diffusing capacity of the lung for carbon monoxide (DLCO); maximum vital 
capacity (Vcmax). * represents p<0.05 when compared with control ** represents 
p<0.01 when compared with control. 
 
4.1.2 MDSC immunophenotyping in the peripheral blood 
Peripheral blood MDSC were characterized by Lineage- HLA-DR- CD33+ CD11b+. M-
MDSC were defined as Lineage- HLA-DR- CD33+ CD11b+ CD14+ and G-MDSC as 
Linage- HLA-DR- CD33+ CD11b+ CD66b+. Isotype control was used as a threshold of 
positive-negative populations (figure 9A). To confirm the morphology of M-MDSC and 
G-MDSC, cells were sorted for staining. Cytospin immunofluorescence stainings of 
CD33 and CD11b confirmed the nuclei morphology of monocytic and granulocytic 
MDSC, respectively (figure 9B and 9C). 
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Figure 9. Characterization of human MDSC in the peripheral blood: (A) Flow 
cytometry analysis is represented by dot-plot graphs of peripheral blood after red 
blood cells lysis. (B) M-MDSC are represented in the histogram plots in green and G-
MDSC in blue. Isotype is represented in gray. Cytospin staining show monocytic and 
granulocytic nuclei morphology of M-MDSC and G-MSDC. (C) CD33 (green) CD11b 
(red) DAPI (blue) immunofluorescence of sorted M-MDSC and G-MDSC. Scale bar is 
5µm. 
 
4.1.3 MDSC is increased in the peripheral blood of IPF and non-IPF patients 
MDSC abundance showed significantly increased in IPF (30.99±15.61%, p=0.0075) 
and non-IPF ILD patients (31.63±15.61%, p<0.05), when compared with controls 
(18.96±8.17%). MDSC abundance in COPD did not significantly change when 
compared with control (25.63±13.94%, p=NS) (figure 10A). 
Next, we quantified the predominant MDSC phenotype in IPF. M-MDSC were 
significantly increased and G-MDSC were significantly decreased in IPF when 
compared with control (figure 10B-C).  
 
Figure 10. MDSC is increased in the whole blood of ILD: (A) Scatter dot plots show 
the % of MDSC (gated in HLA-DR negative cells). Control n=22, IPF n=69, non-IPF 
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ILD n=56, COPD n= 23.  (B) % of M-MDSC (gated in CD33+ CD11b+ cells). Control 
n=22, IPF n=69. (C) % of G-MDSC (gated in CD33+ CD11b+ cells). Control n=22, IPF 
n=69. Statistical analysis was performed using one-way analysis of variance 
(ANOVA) followed by non-parametric Kruskal-Wallis test and Dunnnett’s multiple 
comparison test. For two groups, non-parametric two-tailed Mann-Whitney U test.  * 
represents p<0.05 and **p<0.01 when compared with control. 
 
4.1.4 MDSC abundance correlates with pulmonary function test in IPF 
To explore whether the abundance of MDSC had clinical relevance, we correlated 
the number of MDSC with pulmonary function test (i.e. VCmax). We found that when 
abundance of MDSC was higher the lung function was worse. Abundance of MDSC 
and VCmax significantly correlated in all patients (IPF, non-IPF ILD and COPD) 
pooled together (p= 0.0027, r= -0.24) (figure 11A) and IPF alone (p <0.0001, r=-0.48) 
(figure 11B). However, number of MDSC and VCmax did not show significant 
correlation in non-IPF ILD (p= 0.5, r= -0.07) (figure 11 C) and COPD (p= 0.5, r= -
0.14) (figure 11D). 
 
Figure 11. Increased number of MDSC correlates with VCmax decline in IPF: (A) 
MDSC number negatively correlated with VCmax (% predited) in all diseases (IPF, 
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non-IPF ILD and COPD). (B) MDSC and VCmax correlation in IPF. (C) MDSC and 
VCmax correlation in non-IPF ILD. (D) MDSC and VCmax correlation in COPD. 
Correlation and statistical analysis were determined by Pearson correlation and 
Student’s t distribution.  
 
Moreover, follow-up patients allowed us to study MDSC and VCmax correlation over 
time. For that, we calculated delta (Δ) MDSC and Δ VCmax and then substrate the 
difference of values between visits (V) (Δ=V2-V1). Longitudinal analysis showed that 
MDSC number was reflected on the lung function in IPF only (p=0.0389, r=-0.5773) 
(figure 12a). When we pooled together all the other diseases we did not observe a 
correlation MDSC-VCmax (figure 12b).  
 
Figure 12. Longitudinal analysis show that the increased number of MDSC 
correlates with VCmax decline in IPF disease course: (A) ΔMDSC and ΔVCmax 
correlation in IPF (n=14). (B) ΔMDSC and ΔVCmax correlation in all diseases (IPF 
n=14, non-IPF ILD 11, COPD n=2). Correlation and statistical analysis were 
determined by Pearson correlation and Student’s t distribution.  
 
4.1.5 MDSC suppress lymphocytes proliferation 
To investigate the suppressive function of MDSC in lymphocytes, we performed a co-
culture system with autologous MDSC and lymphocytes. CD4+ and CD8+ cells when 
cultured together with MDSC decreased their proliferation capacity of 70.61±18.73% 
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and 83.69±7.68%, respectively. The suppressive effect of MDSC was observed in all 
patients together (IPF and non-IPF), as well as in IPF alone (figure 13). 
 
Figure 13. MDSC suppress the proliferation of lymphocytes: (A) Histogram shows 
CFSE incorporation in PBMC. Each peak represents one proliferation cell-cycle of 
CD4+ cells for all patients (IPF n=4 and non-IPF ILD n=5) and only IPF, respectively. 
(B) Quantification CD4+ cells proliferation of all patients. (C) Quantification CD4+ cells 
proliferation of IPF patients. (D) Proliferation analysis of CD8+ cells in all patients and 
only in IPF, respectively. (E) Quantification CD8+ cells proliferation of all patients. (F) 
Quantification CD8+ cells proliferation of IPF patients. Statistical analysis was 
performed using paired t-test. * represents p<0.05 and ** p<0.01 
 
4.1.6 IPF patients with high number of MDSC show immunosuppressive 
phenotype  
To determine the immunosuppressive interaction between MDSC and lymphocytes, 
we profiled the lymphocytes in all patients used in the characterized MDSC 
abundance. Lymphocytes gating strategy is represented below (figure 14). T helper 
cells and T cytotoxic cells (effector and non-effector) did not show any significant 
change when compared with control (figure 15). We found a significant decrease of 
CD3+ CD4+ CD8+ (so-called abnormal T cells) in non-IPF ILD when compared with 
control (1.36±1.3% vs 3.14±2.8%, p= 0.0079) (figure 15G). Moreover, CD4+ CD25+ 
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cells (suggestive of Treg cells) were increased in IPF and non-IPF ILD when 
compared with control (52.96±21% p= 0.0002, 55.78±19.8% p= 0.0002, 32.8±17.7%, 
respectively) (figure 16A). So we went deeper into the analysis of Treg cells and 
found that CD4+ CD25+ FoxP3+ cells significantly correlated with MDSC (p= 0.0484, 
r=0.3326) (figure 16B). Moreover, patients with MDSC number higher than 40% 
presented increased mRNA levels of co-stimulatory T cell signals represented by 
CD28, ICOS, ITK and LCK gene expression (figure 16C). 
 
Figure 14. Lymphocytes immunophetyping by flow cytometry: (A) PBMC were 
stained with lymphocytes mix and depicted according to the surface markers. Flow 
cytometry dot-plot shows lymphocytes gated for T helper, T helper effector and T 
helper non-effector cells. (B) Suggestive Treg cells (CD3+ CD4+ CD25+). (C) T 
cytotoxic, T cytotoxic effector and non-effector cells. In all analysis isotype was used 
to differentiate negative/positive cells. 
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Figure 15. Quantification of lymphocytes immunophetyping: (A) Scatter dot-plot 
shows the % of T helper cells gated in lymphocytes. (B) T helper effector cells (CD3+ 
CD4+ CCR7-). (C) T helper non-effector cells (CD3+ CD4+CCR7+). (D) Cytotoxic T 
cells (CD3+ CD8+). (E) Cytotoxic effector T cells (CD3+ CD8+ CCR7-). (F) Cytotoxic 
non-effector T cells (CD3+ CD8+ CCR7+). (G) Abnormal T cells (CD3+ CD4+ CD8+). 
Control n=22, IPF n=69, non-IPF ILD n=56, COPD n= 23. Statistical analyses were 
performed by ANOVA one-followed by non-parametric Kruskal-Wallis test and 
Dunnnett’s multiple comparison test. **p<0.01 when compared with control. 
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Figure 16. Immune-signatures are dysregulated in IPF patients with high number of 
MDSC: (A) Scatter dot-plot shows the % of T cells in Control n=22, IPF n=69, non-
IPF ILD n=56, COPD n= 23. Statistical analyses were performed by ANOVA one-
followed by non-parametric Kruskal-Wallis test and Dunnnett’s multiple comparison 
test. (B) MDSC-Treg cells correlation in IPF. Correlation and statistical analysis were 
determined by Pearson correlation and Student’s t distribution. (C) qPCR 
quantification of CD28, ICOS, LCK and ITK. Control n=14, IPF n=21. Statistical 
analysis was performed using paired t-test. * represents p<0.05, ** p<0.01 and *** 
p<0.001 when compared with control. 
 
4.1.7 MDSC phenotype is neighboring fibrotic regions in IPF lung 
To investigate whether MDSC were localized in IPF lung tissue, we used explanted 
lungs to perform sequential immunofluorescence staining. We found that CD33+ 
CD11b+ cells, suggestive of MDSC, were present in the fibrotic lungs. Moreover, lung 
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MDSC were present in the parenchyma around fibrotic areas positive for α-SMA and 
collagen I (figure 17).  
 
 
Figure 17. Lung-MDSC cells are present in the fibrotic areas in IPF: (A) 
Immunofluorescence staining of fibrotic lungs (IPF n=2, HP n=1) shows CD33 (red) 
and CD11b (green) DAPI (blue). Double positive cells are indicated with squares and 
arrows. (B) CD11b (red) collagen I (green). White squares are the areas in a higher 
magnification (C) CD33 (red) α-SMA (green). Scale bar= 50µm and 20µm. 
 
4.2  Monocytes 
The monocytes work presented in this thesis has been submitted for future 
publication as Greiffo F.R, et al. 
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4.2.1 Patients demographics 
The cohort of the subjects in the immunophenotyping characterization of monocytes 
subsets includes patients diagnosed with NSIP, HP and CTD-ILD. Subjects without 
diagnose of chronic diseases and inflammation were included as controls (Table 4).  
 
 
Table 4. Subjects demographics: data are presented as % and number of affected 
patients (yes/no). Non-specific interstitial pneumonia (NSIP); hypersensitivity 
pneumonitis (HP); connective-tissue diseases (CTD); pulmonary artery hypertension 
(PAH), PAH was determined by echocardiography detecting an increase in mean 
pulmonary artery pressure >25 mmHg; combined pulmonary fibrosis and 
emphysema (CPFE). Immunosuppressor therapy includes azathioprine, 
methotrexate, mycophenolic acid, and rituximab. Lung function data are presented as 
Mean±SD, diffusing capacity of the lung for carbon monoxide (DLCO); forced volume 
capacity of the lung (FVC). * represents p<0.05 when compared with control ** 
represents p<0.01 when compared with control † represents p<0.05 when compared 
with NSIP and HP and †† represents p<0.01 when compared with NSIP and HP. 
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4.2.2 Circulating non-classical monocytes are decreased in ILD  
Monocytes were measured and quantified in PBMCs isolated from fresh peripheral 
blood (Figure 18A). Classical monocytes, defined as HLA-DR+CD14+++CD16-, were 
significantly increased in NSIP and HP subjects compared with controls (89.5±6.8% 
vs 85.78±4.59%, p<0.05 and 90.91±4.89% vs 85.78±4.59%, p<0.01 respectively) 
(Figure 18B). Intermediate monocytes (HLA-DR+CD14+CD16+) abundance did not 
show differences in NSIP, HP and CTD-ILD subjects when compared with control 
(Figure 18C). Non-classical monocytes, defined as HLA-DR+CD14+CD16++, were 
significantly decreased in NSIP, HP, and CTD-ILD subjects compared with controls 
(6.55±5.21% vs 10.34±3.41%, p<0.01, 5.71±4.41% vs 10.34±3.41%, p<0.001 and 
6.62±4.42% vs 10.34±3.41%, p<0.05, respectively) (Figure 18D).  
 
 
Figure 18. Circulating monocytes show decreased composition of non-classical 
monocytes and correlate with DLCO in ILD: (A) PBMC were stained with mAbs, and 
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each monocyte subset was previously defined by HLA-DR+ cells and gated according 
to CD14 and CD16 expression, CD14+++CD16- as classical monocytes, CD14+CD16+ 
as intermediate monocytes, and CD14+CD16++ as non-classical monocytes. Isotype 
was used as a negative control and is represented by gray dots. (B) Flow cytometry 
analysis shows from total monocytes the percentage of classical monocytes. (C) 
Intermediate monocytes. (D) Non-classical monocytes. Control (n=22), NSIP (n=36), 
HP (n= 28), CTD-ILD (n=19). Statistical analysis was performed using one-way 
analysis of variance with non-parametric Kruskal-Wallis test, followed by Dunn’s 
multiple comparison test. * represents p<0.05, and ** represents p<0.01, compared 
with control. (E) Percentage of classical monocytes correlated with DLCO (% 
predicted) in ILD (n=58). (F) percentage of intermediate monocytes correlated with 
DLCO (% predicted). (G) Percentage of non-classical monocytes correlated with 
DLCO (% predicted). For statistical analysis, p values were calculated by Student’s t 
distribution and Pearson correlation. * represents p<0.05 and ** p<0.01. 
Further, we correlated the percentages of circulating monocytes with the forced vital 
capacity (FVC) and diffusing lung capacity for carbon monoxide (DLCO). The 
abundance of classical, intermediate, and non-classical monocytes was not 
significantly correlated with the FVC (% of predicted) (Figure 19D-F). However, 
classical monocytes and non-classical monocytes abundances were significantly 
correlated with the DLCO (% of predicted) (r=-0.2609, p<0.05, and r=0.3202, p=0.01, 
respectively) (Figure 19A-B).  
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Figure 19. Circulating non-classical monocytes do not correlate with FVC: (A) 
Percentage of classical monocytes correlated with FVC (% predicted) in ILD (n=66). 
(B)  Percentage of intermediate monocytes correlated with FVC (% predicted). (C)  
Percentage of classical monocytes correlated with FVC (% predicted). For statistical 
analysis, p values were calculated by Student’s t distribution and Pearson correlation.  
 
Next, NSIP, HP and CTD-ILD subjects were grouped as ILD and divided according to 
treatment: 1) Naïve/untreated, 2) Immunosuppressor (Imm), 3) Glucocorticoid (GC) 
and 4) Immunosuppressor with glucocorticoid (Imm+GC) (Table 4). Classical 
monocytes were significantly increased in patients treated with GC and Imm+GC ILD 
compared with control (93.02±4.35% vs 85.78±4.59%, p<0.01, and 90.3±4.67% vs 
85.78±4.59% p<0.05, respectively), as well in GC-treated patients when compared 
with treatment-naive (93.02±4.35% vs 87.56±6.4%) (Figure 20A). Intermediate 
monocytes did not show difference in naïve and treated ILD subjects when compared 
with control (Figure 20B). Non-classical monocytes were significantly decreased in 
GC, and Imm+GC treated patients when compared with control (3.6±2.86% vs 
10.34±3.41%, and 5.64±3.38% vs 10.34±3.41%, p<0.001, respectively) (Figure 20C), 
as well in GC-treated patients when compared with treatment-naïve (3.6±2.86%, vs 
8.81±4.94%, respectively, p<0.01) (Figure 20C). 
 
Figure 20. Circulating monocytes composition in ILD is associated with treatment: 
PBMCs were stained with mAbs, and each monocyte subset was previously defined 
by HLA-DR+ cells and gated according to CD14 and CD16 expression, 
Interstitial lung diseases 
_________________________________________________________________________________ 
   
 
67 
CD14+++CD16- as classical monocytes, CD14+CD16+ as intermediate monocytes, 
and CD14+CD16++ as non-classical monocytes. Flow cytometry analysis show from 
total monocytes the percentage of (A) classical monocytes; (B) intermediate 
monocytes; (C) non-classical monocytes. Control (n=22), ILD naïve (n=15), ILD 
immunosuppressor (Imm) (n=5), ILD glucocorticoid (GC) (n=31), ILD 
immunosuppressor with glucocorticoid (Imm+GC) (n=32). Statistical analysis was 
performed using one-way analysis of variance with non-parametric Kruskal-Wallis 
test, followed by Dunn’s multiple comparison test. * represents p<0.05, ** represents 
p<0.01 and *** represents p<0.001, compared with control or ILD naïve. 
 
4.2.3 Canonical kinetic and scavenger receptors expression is altered in non-
classical monocytes in ILD  
To fully characterize the immunophenotype of the monocyte populations in ILD, we 
explored the chemokine-receptor expression profile, which distinguishes different 
monocyte subsets (CCR2 in classical monocytes, CX3CR1 in non-classical 
monocytes, and CD163 scavenger receptor in myeloid lineages) (Figure 21A). We 
observed that CCR2 mean fluorescence intensity (MFI) in classical monocytes was 
significantly decreased in ILD subjects when compared with controls (35296±13922 
vs 45104±10034, p<0.001) (Figures 21B). CX3CR1 was decreased in ILD subjects in 
classical and non-classical monocytes when compared with control (3571±1774 vs 
4783±1732, p<0.01 and 8724±3183 vs 10785±2394, p<0.01, respectively) (Figures 
21C and 3F). In contrast, the scavenger receptor CD163 expression was increased 
in non-classical monocytes in ILD subjects compared with control (612.2±588.4 vs 
323.5±64.5, p<0.05) (Figures 21D and 21G). 
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Figure 21. Non-classical monocytes show decreased CX3CR1 and increased 
CD163 expression in ILD. Box and whiskers with dot plot diagrams of flow cytometry 
analysis show the (A) mean fluorescence intensity (MFI) of CCR2, CX3CR1 and 
CD163. (B) CCR2+ classical monocytes; (C) CX3CR1+ classical monocytes; (D) 
CD163+ classical monocytes; (E) CCR2+ non-classical monocytes; (F) CX3CR1+ 
non-classical monocytes; (G) CD163+ non-classical monocytes. For A,B, E, F: control 
(n=20), ILD (n=83). For D and G control (n= 8), ILD (n= 57). Statistical analysis was 
performed using non-parametric two-tailed Mann-Whitney t test. ** represents p<0.01 
and * represents p<0.05 compared with control. 
 
4.2.4 Fractalkine (CX3CL1) drives non-classical monocyte migration and 
accumulation in the lung parenchyma of ILD patients 
In order to understand the mechanisms involved in the kinetic changes of non-
classical monocytes in ILD, we quantified levels of CCL2 and fractalkine (CX3CL1) in 
plasma and lung homogenates of control and ILD lung tissue. We found increased 
CCL2 levels in ILD plasma when compared with controls (301.4±212.5 pg/mL vs 
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128.7±88.21 pg/mL, p<0.001) (Figure 22A). Moreover, CCL2 levels in the lung tissue 
homogenate of ILD and controls did not show a significant difference (Figure 22A). In 
ILD, CCL2 levels were significantly increased in plasma when compared to lung 
tissue (301.4±212.5 pg/mL vs 185.8±134.3 pg/mL, p<0.05) (Figure 22A). Further, 
plasma and tissue concentrations of fractalkine (CX3CL1) in ILD patients were 
significantly increased when compared with controls (0.8166±0.4632 ng/mL vs 
0.5163±0.2377 ng/mL, p<0.01, and 2.049±0.7354 ng/mL vs 1.062±0.4795 ng/mL, 
p<0.001, respectively) (Figure 22B). Controls and ILD subjects showed higher levels 
of CX3CL1 in the lung tissue than in the plasma (1.062±0.4795 ng/mL vs 
0.5163±0.2377 ng/mL, p<0.01, and 2.049±0.7354 ng/mL vs 0.8166±0.4632 ng/mL, 
p<0.001) (Figure 22B). 
Next, to understand the chemoattractant potential of fractalkine (CX3CL1), and 
receptor responsiveness, we performed functional assays in the presence and 
absence of the ligand. In co-culture with endothelial cells, CX3CL1 did not show 
influence on non-classical monocyte adhesion (figure 22C). In contrast non-classical 
monocyte migration was significantly increased in the presence of fractalkine 
(CX3CL1) in ILD subjects (1.38±0.57 fold change vs 1±0, p<0.01) (figure 22D). 
Moreover, monoclonal fractalkine (CX3CL1) antibody decreased non-classical 
monocytes migration when compared with CX3CL1-induced migration and control 
conditions in ILD subjects (0.80±0.85 fold change vs 1.38±0.57 fold change and 
0.80±0.85 fold change vs 1±0, respectively, p<0.05) (Figure 22D). 
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Figure 22. Fractalkine is increased in the lung and drives the migration of pro-fibrotic 
non-classical monocytes in ILD: Enzyme-linked immune assay (ELISA) for CCL2 and 
fractalkine were performed in lung tissue homogenate. (A) CCL2 (pg/mL) in plasma 
(control n=23, and ILD n=63), and lung tissue (control n=9, and ILD n=28); (B) 
CX3CL1 (ng/mL) in plasma (control n=15, and ILD n=44), and lung tissue (control 
n=9, and ILD n=29). (C) In vitro adhesion assay of CD16+ monocytes on the 
activated endothelial cells (TNF-α, 4 hours), control wells were used as an indicator 
of conversion efficiency. Control (n=5) ILD (n=5). (D) In vitro migration assay of non-
classical monocytes, control wells were used as an indicator of conversion efficiency. 
Control (n=13), ILD (n=14). For functional assays, 3-5 experimental replicates were 
use in each experiment. Statistical analysis was performed using non-parametric 
two-tailed Mann-Whitney t test. * represents p<0.05 compared with control ** 
represents p<0.01 compared with control *** represents p<0.001 compared with 
control. 
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Finally, to investigate the accumulation of monocytes in the tissue, we performed 
immunofluorescence staining of lung tissue sections from control and ILD subjects. 
ILD sections showed double positive CD14 and CD16 cells, exclusive monocyte 
markers, outside the vessels (Figure 23A). Quantification of CD14+CD16+ myeloid 
cells localized in the lung parenchyma of explanted ILD subjects was significantly 
increased when compared to controls (0.6744±0.2224% vs 0.3803±0.1001%, 
p<0.05) (Figure 23A). Moreover, immunofluorescence staining showed CD14+CD16+ 
cells expressing CX3CR1+ and CD163+ markers in ILD tissue (Figure 23B-C). Next, 
we observed CX3CR1+CD163+ abundantly in ILD lung tissue (Figure 23D).Lastly, 
CX3CR1+ cells were also positive for CD68 in ILD (figure 23E). 
 
Figure 23. Non-classical monocytes are increased in the lung parenchyma in ILD: 
(A) Immunofluorescence triple staining was performed using explanted lungs from 
control, and ILD. Explanted lungs were stained for CD14 (red), CD16 (green), and 
Von Willebrand factor (vWF) (yellow). Double positive cells are indicated with 
squares and arrows; Graphs bars show the quantification of CD14+ and CD14+CD16+ 
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myeloid cells in the lung parenchyma of control and ILD as % of total cells. Control 
(n= 3), ILD (n=6). (B)  CD14 (yellow), CD16 (green), CX3CR1 (red). Triple positive 
cell is indicated with squares and arrows. (C) CD14 (yellow), CD16 (green), CD163 
(red). Triple positive cells are indicated with squares and arrows. (D) CX3CR1 (red), 
and CD163 (green). (E) CX3CR1 (red), and CD68 (green); CX3CR1 positive cells 
are indicated with red arrows and CD68 with green arrows. Double positive cells are 
indicated with squares and arrows. Cell nuclei are stained by DAPI (blue). All the 
pictures were taken using magnification of 20x (scale bar= 50µm), white squares 
represent higher magnification (scale bar= 10µm). Control (n=3), ILD (n=3). 
Statistical analysis was performed using non- parametric two-tailed Mann-Whitney t 
test. * represents p<0.05 compared with control.  
 
4.2.5 Fractalkine (CX3CL1) is expressed by the lung epithelium and lung non-
classical monocytes express phagocytic phenotype in ILD 
In order to know the lung cell type which is contributing to increased fractalkine 
(CX3CL1) in ILD, we performed immunofluorescence staining that showed CX3CL1 
expression on acetylated tubulin positive cells and on bronchial epithelial regions 
(Figure 24A). To explore phenotypic and functional features of NCM, we looked 
myeloid mature markers, as CD206, and for receptors involved in the apoptotic cell 
clearance and phagocytosis, such as AXL and MERKT.  In ILD, immunofluorescence 
analysis revealed the expression of AXL in CD14+CD16+ cells (Figure 24B), and flow 
cytometry analysis demonstrated that CD14+CD16++ myeloid cells express higher 
levels of MERKT, and mannose receptor (CD206) than CD14+ cells (Figure 24C). 
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Figure 24. Fractalkine is iexpressed on lung epithelium and non-classical monocytes 
expressed phagocytic phenotype in ILD lungs: (A) Immunofluorescence staining was 
performed using explanted lungs and stained for CX3CL1 (red) and acetylated 
tubulin, or collagen type I, or Von Willebrand factor (green). (B) Triple 
immunofluorescence staining for CD14 (yellow), CD16 (red), and AXL (green). 
Pictures were taken using magnification of 40x (scale bar= 20µm), white squares 
represent higher magnification (scale bar= 10µm). Cell nuclei are stained by DAPI 
(blue). Control (n=3), non-IPF ILD (n=3). (C) Flow cytometry analysis and 
quantification (percentage and absolute numbers) of CD45+ lung cells suspension. 
Monocytes were gated in CD15- HLADR+ cells.  Control (n=4), ILD (n=8). 
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This thesis focuses on the functional characterization of circulatory MDSC and 
monocytes trafficking to the lung in ILD. In IPF, the number of MDSC is increased in 
the peripheral blood. The higher the number of MDSC, the more limited the lung 
function of the patient is. In ILD, pro-fibrotic non-classical monocytes (NCM) are 
decreased in the peripheral blood and increased into the fibrotic lungs. NCM-derived 
cells in the ILD lungs co-stained with CX3CR1, M2-like and phagocytic markers.  
Myeloid cells contribution to lung remodeling, as well as repair and regeneration in 
ILD has gained important attention in the last years. Recently, a mouse study using 
GFP-membrane localized myeloid lineage as fibroblast-like cells in the skin wound 
which suggests a mesenchymal phenotype of myeloid progenitor (Sinha et al., 2018). 
In cell culture system, increased number of myeloid cells showed to contribute to 
organoid formation and suggested to revert lung injury in lung regeneration in a 
mouse model (Lechner et al., 2017). Here, MDSC and monocytes, both derived from 
myeloid progenitor cell niche, were quantified by flow cytometry. In MDSC 
quantification, cell abundance correlated with disease severity and suggested to be a 
potential biomarker for IPF (Fernandez et al., 2016). Classical monocytes were found 
to be increase in the peripheral blood of ILD patients while non-classical monocytes 
were decreased. Our studies show that myeloid cells abundance is an important 
predictor of disease status and predictor of tissue injury. Cell abundance is an 
important and the first one result to be questionable in cell recruitment the site of 
injury (Yona et al., 2013). Importantly, the results here presented showed imbalance 
between compartments and recruitment of cells in response to the injury. Recently, 
scRNA-seq identified in lung fibrosis mouse model a transitional population of 
monocyte-derived CX3CR1+ cells that were localized in the fibrotic niche and 
contributed to fibroblast accumulation (Aran et al., 2019). Further, the abundance of 
MDSC, a cell type which is recruited in case of injury, are also related to the 
recruitment of tumor-associated macrophages (Ugel, De Sanctis, Mandruzzato, & 
Bronte, 2015). 
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Lately, it has been assumed that the crosstalk between mesenchymal and myeloid 
cells is an important regulator of tissue injury (Reyfman et al., 2018), as well repair 
(Lechner et al., 2017). Indeed, the activation and proliferation of stromal cells showed 
to be correlated with immunosuppressive factor, alteration on the cell surface and 
production of growth factors (Nowarski, Jackson, & Flavell, 2017).  Here, MDSC and 
monocytes showed to contribute to ILD and increase lung injury mechanisms. 
Importantly, MDSC and monocytes were phenotypically described and classified 
according to cell surface expression characterizing cell subsets. The characterization 
of cell subsets is important to functional assessment (Yoon et al., 2014). This is 
illustrated with the results from Jason Rock’s laboratory, as well as the results 
presented here. In these, 1) tissue regeneration driven by CCR2+ myeloid cells 
(Lechner et al., 2017) and 2) our data which tissue injury is suggested to be driven by 
an imbalance in the CX3CR1- fractalkine axis increased the infiltration of pro-fibrotic 
non-classical monocytes. Therefore, we emphasize that the phenotype analysis of 
immune-stromal interaction cells is crucial. Next, for a better and clearer discussion, 
the following text is divided in MDSC and monocytes sub-sections. 
 
5.1  MDSC 
The MDSC discussion presented in this thesis has been partly published by 
Fernandez I.E, Greiffo F.R, et al. PMID: 27587556, ERJ, 2016 (Appendix 1). Here, 
we showed the accumulation of MDSC in the peripheral blood and lung tissue in non-
IPF ILD patients. Moreover, the higher number of MDSC worse the lung function 
showed to be in cross-sectional as well longitudinal analysis. Next, increased 
circulatory CD4+CD25+ T regulatory cells were detected in IPF. Additionally, MDSC 
and Tregs (CD4+CD25+ FoxP3+) showed a positive correlation. Further, IPF patients 
with high number of MDSC showed decreased RNA levels of CD28, ICOS, ITK, and 
LCK in PBMC. Finally, culturing autologous MDSC and lymphocytes revealed the 
functional assessment of MDSC decreasing CD4+ and CD8+ cells proliferation. 
Taking together, we showed a new immunosuppressive role in the circulating blood 
which reflects disease status in IPF.  
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5.1.1 Immunosuppressive phenotype and function of MDSC 
It is known that the innate and adaptive immune cells can enhance the secretion of 
pro-fibrotic factors contributing to fibrogenesis (Wynn, 2011). Immunosuppressive 
therapy in IPF (e.g. prednisone and azathioprine) has been not recommended due to 
its harmful effects. Furthermore, immunosuppressive therapy showed to increase 
mortality in IPF patients (Raghu, Anstrom, King, Lasky, & Martinez, 2012). Our data 
shows that there is a MDSC-immunosuppressive network in the peripheral blood and 
in the lungs of IPF patients. Therefore, in our opinion the immunosuppressive 
therapies used to treat IPF patients in the past will perpetuate the limited immune 
defense and so the lung injury. 
Furthermore, T cells dysregulation play an important role in IPF (Lo Re, Lison, & 
Huaux, 2013). Importantly, lymphoid tissue formation has been reported to be 
involved in fibrotic niches of IPF lungs increasing the migration of activated T and B 
cells (Marchal-Somme et al., 2006). Moreover, circulating CD25+ FoxP3+, suggestive 
of T reg, and CD4+ cells express CD28, a marker which related  to worse prognosis 
in IPF (Gilani et al., 2010). Also, IPF patients showed to have low abundance of Treg 
cells in the BAL (Kotsianidis et al., 2009). In our data we identified decrease 
CD4+CD25+FoxP3+ cells in IPF which correlated with the abundance of MDSC. . In 
summary, the less MDSC number, less T reg cells were circulating in the peripheral 
blood of IPF patients. Additionally, autologous cell culture of MDSC and lymphocytes 
showed that the proliferation of CD4 and CD8 positive lymphocytes was decreased. 
Here, our data confirmed the immunosuppression role driven by lymphocytes in IPF. 
Strikingly, we reported for the first time that MDSC play a role in the 
immunosuppression response in IPF blood and tissue.  
 
5.1.2 MDSC biomarker 
In cancer, measurement of MDSC has been considered a biomarker clinical 
outcome. Moreover, MDSC measurement can help to identify mechanisms involved 
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in disease progression, therapy response and survival in cancer (Walter et al., 2012) 
(Wang et al., 2014). Also, MDSC abundance has been shown to correlate with 
cancer stage (Vasquez-Dunddel et al., 2013). In past years, IPF has been compared 
with cancer diseases. It seems that IPF and cancer share many of pathogenic 
pathways, such as Tregs, PDGF, TGF-ß, and now MDSC. Therefore, we think that 
MDSC are a potential biomarker for IPD which reflects disease status, data 
presented here. In our opinion, MDSC quantification and mechanisms can reflect 
disease prognosis. For the future, MDSC quantification should be done in different 
cohorts. Finally, longitudinal studies will clarify MDSC applicability in medical 
treatment and survival. 
 
5.1.3 MDSC in the lung tissue  
MDSC in the lung tissue have been described in non-small cell lung cancer. Within 
the lung, high abundance of MDSC interplays with tumor development and disease 
development (Srivastava et al., 2008) (Feng et al., 2012) (Zhang et al., 2009). 
Moreover, in other lung diseases (i.e. cystic fibrosis, tuberculosis, pulmonary 
hypertension and COPD) MDSC number is increased and showed to be associated 
with pathophysiology (Rieber et al., 2013) (du Plessis et al., 2013) (Yeager et al., 
2012). In COPD, recent work demonstrated an effector T-cell dysfunction composed 
by T regs, MDSC and PD-1 exhausted effector T cells (Kalathil et al., 2014). In our 
data, the number of MDSC in COPD patients did not show a significant increase. In 
fact, our COPD cohort was younger than Kalathil et al.’s cohort. Also, Kalathil et al.’s 
cohort presented worse lung function data than our cohort. In this line, Verschoor et 
al. showed that MDSC abundance is affected by age (Verschoor et al., 2013). We 
are aware of the differences between our IPF and control cohorts. The control group 
has an average of 55.4 years old which is younger than the IPF group with an 
average of 68.2 years old. In our opinion, the difference of 12.8 years (IPF and 
controls) is much less than Verschoor et al.’s study which the health young adults 
presented an average of 32 years old (20 years younger than the average age of 
controls used here). 
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Next, the abundance of MDSC inversely correlated with pulmonary function test, 
VCmax. IPF patients showed a better correlation of MDSC and VCmax than non-IPF 
and COPD patients. This could be due to differences in pathophysiology. As 
referenced in the introduction, IPF has the worse prognosis and faster progression 
than other ILD, as well applicable to COPD. Moreover, we showed CD33+CD11b+ 
cells neighboring fibrotic areas in the lung tissue. This data suggests a migratory 
capacity of MDSC to the site of injury, as well supports the negative correlation 
between circulating MDSC and worse VCmax. Recently, we measured MDSC by 
flow cytometry in the lung cell suspensions of ILD and control lungs (figure 25). 
Strikingly, our new data fully supports MDSC phenotype analysis and quantification 
in lung tissue. 
 
 
Figure 25. MDSC characterization and quantification by flow cytometry in control and 
ILD lungs: (A) FACS plot of lung cell suspension in control. Beads isolated CD45+ 
cells stained and gated in Linage negative (Lin-): CD56, CD20, CD19, CD16, CD3; 
HLA-DR negative, CD33 and CD11b double positive. (B) ILD (HP) lung cells. (C) 
Quantification of MDSC in control (n=4) and ILD (IPF n= 3, NSIP n=2, HP n=3).  
Statistical analysis was performed using non-parametric two-tailed Mann-Whitney t 
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5.1.4 MDSC profiling  
Cell profiling is value tool to investigate fibrosis. For instance, transcriptome data in 
the blood of IPF versus control identified 1428 genes expressed in mild IPF and 2790 
genes expressed in severe IPF (Yang et al., 2012).  Moreover, four genes expressed 
in PBMCs have been described as important IPF outcome predictor. CD28, ICOS, 
ITK, and LCK are IPF predictors. Interestedly, the downregulation of these four 
genes showed to be a better outcome than only clinical data (Herazo-Maya et al., 
2013). Here, we showed that IPF patients with high number of circulating MDSC 
presented downregulation of decreased RNA levels of CD28, ICOS, ITK, and LCK in 
PBMCs. Therefore, our data supports the downregulation of these genes in IPF 
versus control, as well the role of MDSC as an important player in IPF.  
Moreover, the characterization and interplay of MDSC and other immune cells is 
crucial for therapeutic target. MDSC is known to suppress the function of immune 
cells inducting pro-fibrotic factors (i.e. Tregs, TGF-ß) (Marvel & Gabrilovich, 2015). 
Further, it has been described that MDSC can differentiate into other cell types, such 
as tumor-associated macrophages and dendritic cells, at the site of injury (cancer) 
(Corzo et al., 2010; Franklin et al., 2014) (Zhong et al., 2014). Both, macrophages 
and dendritic cells can be derived from monocytes. Also, our data show monocytic 
MDSC is more predominant than granulocytic MDSC in IPF. Therefore, we sought to 
characterize the differences between circulatory MDSC and monocytes. Autologous 
MDSC and monocytes from IPF patients (n=10) were sorted out by flow cytometry 
and magnetic beads, respectively. Label-free quantitative mass spectrometry 
revealed 7000 proteins in total.  Comparing the MDSC and monocytes sets of 
proteins, 502 proteins were enriched in MDSC and 1224 in monocyte. Cell-cell 
communication showed a combination of 200 ligands and 153 receptors between 
MDSC and monocytes. Autocrine signaling edges: 1) monocyte to monocyte showed 
a combination 339 proteins; and 2) MDSC to MDSC showed a combination 290 
proteins. Monocyte to MDSC showed a combination 311 proteins and MDSC to 
monocytes, 316 proteins (figure 26).  
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Figure 26. MDSC and monocytes proteomics data. (A) Autologous monocytes and 
MDSC protein isolation. (B) Vulcan plot analysis of exclusive proteins expressed by 
monocytes or MDSC. (C) Autocrine and paracrine signals in monocytes and MDSC. 
Principal component analysis (PCA) was done by Prof. Alistair Forrest and his group 
(Harry Perkins Institute of Medical Research, Murdoch, Australia) (unpublished data). 
 
5.2  Monocytes 
The monocytes discussion presented here is part of the publication “CX3CR1-
fractalkine axis drives kinetic changes of monocytes in fibrotic interstitial lung 
diseases” for future publication. We used a multi-compartment (blood and lung) 
approach to show that CX3CR1-fractalkine axis plays functional implications on pro-
fibrotic non-classical monocytes (NCM) recruitment in ILD (Figure 27). In ILD, 
peripheral blood NCM were decreased and positively correlated with worse DLCO 
which resembled a severe disease phenotype. Mechanistic studies indicated that 
monocytes-derived cells in the lung tissue were recruited from the circulation to the 
lungs through CX3CR1-fractalkine interaction. Our findings suggest decreased 
abundance of NCM CX3CR1+ in the peripheral blood due to a fractalkine imbalance 
between lung and blood compartments mediating the increased CD14+CD16++ 
myeloid cells population expressing CX3CR1 and M2-like markers in ILD lungs. 
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These analyses support a new perspective of myeloid cells phenotype and 
recruitment in ILD.  
  
Figure 27. CX3CR1-fractalkine axis enhances pro-fibrotic non-classical monocyte 
migration into ILD lungs: representative scheme shows an overview of monocyte 
subsets role and function in healthy (left) and ILD (right) lungs. Non-classical 
monocytes are decreased in the blood of ILD patients. Diffusing lung capacity of 
carbon monoxide (DLCO) is decreased in ILD. Fractalkine (CX3CL1) levels are 
higher in the lungs than in the blood of ILD patients, and expressed by epithelial 
cells. Non-classical monocyte migration is increased in the presence of fractalkine in 
ILD. Non-classical monocytes-derived cells express CX3CR1, CD163, CD206, AXL 
and MERKT in ILD lungs.  
 
5.2.1 Monocytes subsets and abundance in the peripheral blood 
Monocyte subset frequencies are well defined in human as approximately 85% 
classical (CM), 5% intermediate (IM) and 10% non-classical (NCM). However, under 
pathological conditions the frequencies of monocyte subsets vary and respond 
differently as a consequence of the stimuli (Boyette et al., 2017). Frequencies of 
circulating classical and non-classical monocytes have been reported to increase in 
cases of high inflammation, such as severe infection, rheumatoid arthritis, 
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atherosclerosis, Crohn’s disease, and hematological malignancy (Soehnlein et al., 
2008; J. Yang, Zhang, Yu, Yang, & Wang, 2014; Ziegler-Heitbrock, 2015). High 
inflammatory diseases switch the percentage of monocytes due increases in TNF-α, 
rheumatoid factors, IL-6, IL-1ß, and granulocytes (Soehnlein et al., 2008; J. Yang et 
al., 2014). Our results show that CM were significantly increased whereas NCM were 
significantly decreased, in the peripheral blood in ILD when compared with control. 
When we correlated these results with DLCO, we observed that higher number of 
CM, as well as, lower numbers of NCM significantly correlated with worse DLCO.  
Recently, a longitudinal study reported increased abundance of monocytes in the 
peripheral blood of early stage-ILD patients significantly associated with lung 
abnormalities and lower FVC (Podolanczuk et.al, 2018). However, FVC did not show 
a significant correlation with monocytes subsets, PFT (DLCO and FVC) indicated that 
our cohort included patients with severe lung function parameters suggestive of late 
inflammation phase and extensive fibrotic status of ILD. This might explain the 
differences on our data and inflammatory diseases that showed increased 
frequencies of circulating CM and NCM (Ziegler-Heitbrock, 2015) (J. Yang et al., 
2014). 
In the past, non-classical monocytes in mice were shown to be associated with the 
initial inflammatory response by releasing tumor necrosis factor alpha (TNF-α) 
developing inflammatory arthritis (Misharin et al., 2014). We think that these results 
might be due to a vascular injury, which is known to happen in pulmonary fibrosis, 
and a possible NCM infiltration into the lung injury. On the other hand, we think that 
the correlation between NCM and DLCO parameters suggests being a result of NCM 
accumulation on the pulmonary vessels decreasing the DLCO.  
Another important point to discuss is the effect of glucocorticoid treatment on 
monocytes subsets. Our cohort included treated ILD and a few number of naive 
patients (untreated). Thus, to address to point in depth, we performed experiments in 
which we isolated monocytes from controls and treated them with different doses of 
methylprednisolone, as previously reported (Frankenberger, Haussinger, & Ziegler-
Heitbrock, 2005). Then, we found that CM and NCM treated with methylprednisolone 
for 24 hours did not show changes in cell number. However, we found increased 
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number of intermediate monocytes (IM) treated with 10-9 M of methylprednisolone 
(figure 28). Not long ago, it has been described that the abundance of intermediate 
monocytes is associated to systemic glucocorticoid treatment in uveitis patients (Liu 
et al., 2015).  Here, we did not find increased numbers of circulating IM in ILD. 
Taking together, our results show that steroid therapy does not affect mature 
circulating monocytes populations in ILD. However, in our case, it might influence 
monocyte activation and migration, as previously showed in healthy volunteers 
(Ehrchen et al., 2007). Moreover, in the study of Varga et al. dexamethasone 
treatment in cultured monocytes decreased the expression CX3CR1 and CD163 
(Varga et al., 2008). We think that these findings support our data which show 
decreased CX3CR1 expression in NCM in treated ILD patients. On contrary, we 
show increased CD163 expression in NCM. In our opinion, the fact that only NCM 
showed increased expression of CD163 in treated ILD patients is suggestive of 
potential pro-fibrotic and M2 like macrophage phenotype.  
 
Figure 28. Glucocorticoid effect on monocytes (whole blood and isolated 
monocytes): different concentrations of methylprednisolone were added or not in cell 
culture medium of freshly isolated monocytes. Flow cytometry was performed to 
quantify percentages of classical, intermediate and non-classical monocytes. For 
methylprednisolone experiments (n=3). Statistical analysis was performed using non-
parametric two-tailed Mann-Whitney t test. * represents p<0.05 compared with 
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control ** represents p<0.01 compared with control *** represents p<0.001 compared 
with 24h without methylprednisolone. 
 
5.2.2 Non-classical monocytes infiltration into fibrotic lungs 
Next, we sought to determine if circulating NCM are decreased in the peripheral 
blood of ILD due to an active adhesion to the endothelium or migration to the injured 
organ contributing to pulmonary fibrosis. In this line, CCR2 and CX3CR1 are known 
to be chemokine receptors which are important in monocyte phenotyping, as well in 
subset function (Ziegler-Heitbrock, 2007). In our data, we observed that ILD patients 
with a low frequency of non-classical monocytes also showed decreased expression 
of chemokine receptors in the peripheral blood. Here, global MFI levels of CCR2 
were decreased in classical monocytes and CX3CR1 were decreased in CM and 
NCM. Importantly, when chemokine receptors are engaged in chemotaxis, they can 
be transiently removed from the cell surface by ligand-receptor internalization or 
clathrin-mediated endocytosis (Springer, 1994). Thus, we think that an active 
receptor-ligand interaction might explain the decrease of CCR2, and CX3CR1 in non-
IPF ILD patients.  
We know that chemokine receptors are highly responsive to their ligands (Landsman 
et al., 2009; Osafo-Addo & Herzog, 2017). For instance, CCR2 responds to multiple 
ligands, including CCL2 (Nomiyama, Osada, & Yoshie, 2013). On contrary, CX3CR1 
responds exclusively to its ligand fractalkine (CX3CL1) (Nomiyama et al., 2013). The 
major role of the CX3CR1-fractalkine axis is to mediate chemotaxis, adhesion, and 
transmigration of leukocytes (Ge et al., 2016). In our data, we observed increased 
CCL2 and fractalkine levels in the plasma in ILD versus control. However, in the 
lungs, only fractalkine was increased in ILD versus control. When we analyzed the 
differences of CCL2 and fractalkine levels between compartments, lung and plasma: 
1) CCL2 plasma levels were higher than in the lungs in ILD patients; 2) fractalkine 
levels in the lung were higher than in the plasma in ILD patients. In our opinion, this 
might suggest active monocyte recruitment from the bone marrow by CCL2 and 
supporting our data by the increase in classical monocytes in the circulation and 
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could explain the decreased levels of CCR2 by receptor internalization, as previously 
described (Cardona et al., 2008). Also, our data show an imbalance of fractalkine 
levels between the blood and lung compartments, which we think might be related to 
an increased infiltration of CD14+CD16+ myeloid cells into fibrotic lungs. Following-up 
in the function of fractalkine, we performed migration and adhesion assays in the 
presence of CX3CL1. First, NCM adhesion capacity in the presence of CX3CL1 did 
not show changes. However, we observed that in ILD patients only, CX3CL1 
increased NCM migration.  
CX3CR1-fractalkine axis is a key-mediator of monocyte adhesion and migration (Lee, 
Lee, Song, Lee, & Chang, 2018). In fibrosis, for instance in the skin, CX3CR1 axis 
regulated tissue fibrosis by TGF-β and CTGF production and enhancing collagen 
deposition (Arai et al., 2013). In our data, we showed that the source of fractalkine in 
pulmonary fibrosis is the bronchium epithelium. Certainly, the crosstalk between 
myeloid and epithelial cells is an important regulator of lung-immunity, whereas 
monocytes and M2-like macrophages modulate ATII survival and proliferation 
(Lechner et al., 2017).  In this line, we also detected an increased expression of the 
CD163 scavenger receptor exclusively in NCM in ILD. CD163 is a scavenger 
receptor, and marker of macrophage alternative activation (Pilling, Fan, Huang, Kaul, 
& Gomer, 2009). CD163 is a marker related to cell debris and apoptotic body 
removal. Furthermore, CD163 showed to be highly expressed in cultured fibrocytes 
(Canton, Neculai, & Grinstein, 2013), CD14+ circulating cells in scleroderma-ILD 
patients, and in the tissue of several types of ILD (S. K. Mathai et al., 2010; Prasse et 
al., 2006). Also, the scavenger receptor CD163 expression is considered an innate 
immune sensor due to the TNF-α production under infection (Fabriek et al., 2009). 
Therefore, the higher expression of CD163 in our cohort together with 
CX3CR1+CD68+ myeloid cells in the lung parenchyma of ILD patients, might suggest 
a M2-like macrophage signature of NCM. In summary, these results highlight an 
important link between CD16+ monocytes, CX3CR1, CD163 expression, and 
monocyte-derived macrophages in the lung tissue. Additionally, macrophages 
expressing CX3CR1 may support a potential role of NCM progenitor cells of 
macrophages in the lung.  
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5.2.3 Non-classical monocytes phenotype in the fibrotic lungs 
In fact, depicting myeloid cell function for therapeutic or regenerative medicine 
applications requires a comprehensive understanding of what drives the localization 
and fate of these cells (Misharin et al., 2017). In this line, genetic linage tracing 
experiments show that increases in alveolar macrophages during fibrosis is 
attributable to recruited monocytes-derived cells, carrying a fibrotic transcriptome 
profile (Misharin et al., 2017). A recent study using CX3CR1 knockout mice showed 
decrease mRNA and protein levels of TGF-ß in mouse model of pulmonary fibrosis 
on days 3, 7 and 14 (Ishida et al., 2017). More recently, scRNA-seq data showed that 
fibrotic lung-macrophages expressing CX3CR1 are localized on fibroblast-site 
increasing the secretion of PDGF (Aran et al., 2019). Although the approach we used 
here did not trace circulating NCM CX3CR1+ cells, it has been proved by genetic 
linage tracing experiments that increases in alveolar macrophages during fibrosis, is 
attributable to recruited monocytes-derived cells carrying a fibrotic transcriptome 
profile (Misharin et al., 2017).  
In our data, we found expression of fractalkine by the bronchium epithelium which we 
think is a modulator of non-classical monocyte migration in ILD. On these thoughts, 
we know that loss of epithelial cell integrity as one of the hallmarks in lung fibrosis 
(Rock et al., 2011). We found that only in ILD, CD14+CD16+ cells expressed AXL. 
Our results are consistent with previous findings which showed rare immune cells 
localized in the fibrotic lung parenchyma expressing AXL (Espindola et al., 2018).  
Recently, AXL which is part of the TAM (Gas6/TYRO3, AXL, MERKT) family, has 
been reported as an important player in epithelial cell injury and an important target 
to decrease lung fibrosis (Espindola et al., 2018; Fujino, Kubo, & Maciewicz, 2017). 
We observed CD14+CD16++ myeloid cells increased in the ILD lungs. We found that 
only in ILD, CD14+CD16+ cells expressed AXL. Here, we show that NCM in the 
fibrotic parenchyma of ILD patients in expressed AXL. Therefore, we think that the 
rare immune cells described by Espindola et al. (Espindola et al., 2018) are NCM 
which migrate to extravascular compartment though fractalkine which has been 
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cleavage in response to epithelial cell injury known to happened in pulmonary 
fibrosis. Linked to CD163 scavenger receptor, AXL and MERTK signaling contributes 
to the “eat-me signals” which recognizes phagocytosis process by receptor activation 
(Li, 2012). Furthermore, CD14+CD16++ myeloid cells in the ILD lung expressed 
MERTK and macrophage mannose receptor CD206. 
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6. Conclusions and future directions 
Pulmonary fibrosis is a detrimental and complex disease. Ultimately, disease 
progression leads to alteration of the lung pathophysiology and death. The treatment 
is limited, for IPF the prescription of pirfenidone and nintedanib (both anti-fibrotic 
drugs) will slow-down disease progression. NSIP, HP and CTD-ILD are treated with 
glucocorticoid which may not be benefic to fibrosis. Therefore, there is an urgent need 
of a complete understanding and identification of cellular and molecular players in all 
types of ILD. With that, it would be possible to determine in-depth mechanisms of 
effective therapies. 
In our first study presented here, MDSC has been suggested to be a novel and 
potential biomarker for IPF. Also, MDSC affected lymphocytes response. Therefore, 
the control of MDSC abundance and migration to the lungs via exclusive targets 
expressed by MDSC can reduce immune dysregulation in IPF. Moreover, network 
analysis of autocrine and paracrine signatures found in MDSC and monocytes lead to 
targets in which can be applicable in new treatment.  Identification of specific proteins 
expressed by MDSC leads a potential research field.  
Second, the monocytes study presented here showed that monocytes phenotypes 
may help the management of pulmonary fibrosis and provide novel therapeutic 
strategies to either restore monocyte function or modulate recruitment. In this study 
we identified a compartmental imbalance of fractalkine levels mediating the migration 
of NCM-CX3CR1 into human fibrotic lungs. Furthermore, NCM-derived cells 
expressed M2-like phenotype and phagocytosis markers in the ILD lungs. Therefore, 
targeting CX3CR1-fractalkine axis may aid the management of end-stage ILD and 
provide novel therapeutic strategies to either restore monocyte function or modulate 
recruitment. Interestingly, fractalkine cleavage has been reported to be associated 
with over-expression of disintegrin and metalloproteinase 10 (ADAM10) 
(Hundhausen et al., 2003). The fractalkine shedding via ADAM10 is currently under 
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ABSTRACT Idiopathic pulmonary fibrosis (IPF) is a fibroproliferative disease with irreversible lung
function loss and poor survival. Myeloid-derived suppressor cells (MDSC) are associated with poor
prognosis in cancer, facilitating immune evasion. The abundance and function of MDSC in IPF is
currently unknown.
Fluorescence-activated cell sorting was performed in 170 patients (IPF: n=69; non-IPF interstitial lung
disease (ILD): n=56; chronic obstructive pulmonary disease (COPD): n=23; healthy controls: n=22) to
quantify blood MDSC and lymphocyte subtypes. MDSC abundance was correlated with lung function,
MDSC localisation was performed by immunofluorescence. Peripheral blood mononuclear cell (PBMC)
mRNA levels were analysed by qRT-PCR.
We detected increased MDSC in IPF and non-IPF ILD compared with controls (30.99±15.61% versus
18.96±8.17%, p⩽0.01). Circulating MDSC inversely correlated with maximum vital capacity (r=−0.48,
p⩽0.0001) in IPF, but not in COPD or non-IPF ILD. MDSC suppressed autologous T-cells. The mRNA
levels of co-stimulatory T-cell signals were significantly downregulated in IPF PBMC. Importantly,
CD33+CD11b+ cells, suggestive of MDSC, were detected in fibrotic niches of IPF lungs.
We identified increased MDSC in IPF and non-IPF ILD, suggesting that elevated MDSC may cause a
blunted immune response. MDSC inversely correlate with lung function only in IPF, identifying them as
potent biomarkers for disease progression. Controlling expansion and accumulation of MDSC, or blocking
their T-cell suppression, represents a promising therapy in IPF.
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Idiopathic pulmonary fibrosis (IPF) is a chronic and lethal fibroproliferative disease of the lung, with
unknown aetiology. IPF is characterised by an irreversible loss of lung function with a median survival, or
time to lung transplantation, of 2–3 years after diagnosis. The natural history of IPF is highly variable and
unpredictable between patients [1]. In the past years, many advances have been accomplished with respect
to better delineating dominant pathomechanisms and improved diagnosis, monitoring or treatment of IPF.
These efforts have led to the approval of two new therapeutics, pirfenidone and nintedanib, which slow
down lung function decline in IPF [2].
While the exact pathophysiology of IPF remains unknown, several key drivers of disease initiation and
progression have been unravelled, including repetitive microinjuries to the bronchial and alveolar
epithelium [3], aberrantly activated fibroblast phenotypes, and excessive extracellular matrix (ECM)
accumulation [4]. While nonspecific immunosuppressive therapy remained without benefit in a number of
clinical studies, recent findings of gene expression signatures and peripheral blood biomarker profiling
have highlighted the possibility of immune system dysfunction in IPF pathogenesis (e.g. correlating gene
expression levels with B- and T-cell activation [5–8]).
Importantly, innate and adaptive immunity contributes to fibrogenesis in a number of organs [9]. The
recent literature has provided increasing evidence for a pro-inflammatory signature in peripheral blood
and lung tissue of IPF patients, including aberrantly activated lymphocyte/monocyte populations [10]. In
IPF, circulating leukocyte phenotypes, for instance CD4+ T-cells, display reduced levels of CD28,
suggesting persistent antigen-driven proliferation and possibly clonal exhaustion [6]. These data are
supported by recent transcriptome analysis of peripheral blood mononuclear cells (PBMCs) in which the
co-stimulatory T-cell signal (assessed by mRNA levels of CD28, ICOS, LCK and ITK) was downregulated
and predicted poorer survival in IPF patients [7]. Semaphorin (Sema) 7a-positive T-regulatory (T-reg)
cells are increased in rapidly progressive IPF patients [5], thus supporting the role of dysregulated T-cell
responses in IPF.
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells with
potent suppressor capabilities, which are associated with poor prognosis in cancer [11]. MDSCs contribute
to tumour-immune cell evasion by suppressing T-cell responses [12]. Currently, MDSCs are not classified
by a standard leukocyte lineage marker, since MDSCs are comprised of various immature cells of myeloid
origin, including myeloid-progenitor cells, immature monocytes or dendritic cells, or immature
granulocytes. Two important subsets of human MDSCs have been reported: monocytic MDSC
(mo-MDSC) with a lineageneg/HLA-DRneg/CD33+/CD11b+/CD14+ phenotype, and granulocytic MDSC
(g-MDSC) with a lineageneg/HLA-DRneg/CD33+/CD11b+/CD14−/CD15+/CD66b+ phenotype [13]. The
accumulation of MDSCs is a common finding in malignancies, including lung cancer, but also in many
other pathological conditions, such as transplantation [14], infection [15] or autoimmunity [16]. In
nonsmall cell lung cancer, patients with higher amounts of peripheral MDSCs had poorer survival or
response to chemotherapy [17]. In chronic inflammatory processes of the lung, such as tuberculosis (TB)
[18] or Pseudomonas aeruginosa infection secondary to cystic fibrosis [19], MDSCs induce T-cell
suppression to avoid immune surveillance and undermine host defence. In COPD, a suppressive network
comprised by T-reg cells, PD-1+ T-cells and MDSCs counteract the inflammatory immune reaction and
mitigate innate antibacterial and antiviral properties [20].
Importantly, the contribution of MDSCs in fibrotic lung disease, including IPF, has not been elucidated at
all to date [21]. Therefore, in this study we performed, for the first time, an in-depth characterisation of
MDSCs in the peripheral blood and lung tissue of IPF patients and correlated their levels with parameters
of disease severity. Intriguingly, MDSCs inversely correlate with lung function and can be detected in lung
tissue of IPF patients, highlighting their potential contribution to IPF pathogenesis.
Materials and methods
For in-depth details on the material and methods, refer to the supplementary material.
Patients and control group
We prospectively included 170 patients in the analysis, divided into 69 IPF, 56 non-IPF ILD (hypersensitivity
pneumonitis: n=17, nonspecific interstitial pneumonia: n=27, connective tissue disease-ILD: n=12) and 23
COPD patients, as well as 22 healthy controls. Patients were recruited at the Comprehensive Pneumology
Center (Munich, Germany) from June 2014 to July 2015 (table 1). 22 healthy volunteers (table 1) were free
from signs of current infection, inflammation or respiratory symptoms at the time of blood sampling.
Informed written consent was obtained for all participants, study methods were approved by the local ethical
review board. Diagnosis of IPF was performed by multidisciplinary consensus, based on current American
Thoracic Society/European Respiratory Society criteria [22].
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Cell isolation and flow cytometry analysis
For immunophenotyping, fresh venous blood was collected in EDTA-coated vacutainer tubes (Sarstedt,
Nümbrecht, Germany). Briefly, whole blood or PBMC buffy coats were used for flow cytometry detection
of MDSC and lymphocyte subtypes. MDSC were gated as lineageneg/HLA-DRneg/CD33++/CD11b+/CD14+
or lineageneg/HLA-DRneg/CD33+/CD11b+/CD66b+, and data presented as % gated HLA-DRneg cells.
%mo-MDSC and %g-MDSC was determined and presented as % gated CD33++ CD11b+ and CD33+
CD11b+, respectively. Lymphocyte subtypes were determined as T-cells (CD3+), T-helper (CD3+CD4+)
(effector (CCR7−) and non-effector (CCR7+)), T-cytotoxic (CD3+CD8+) (effector (CCR7−) and
non-effector (CCR7+)), abnormal T-cells (CD3+CD4+CD8+) and T-reg cells (CD4+CD25+ and
CD4+CD25+FoxP3+), with the antibody list detailed in figure E1 and table E1, as previously reported [23].
For whole blood staining, 100 µL was incubated with an antibody mix for MDSC (table E1) for 20 min at
4°C in the dark. Erythrocytes were lysed with a Coulter Q-Prep working station (Beckman Coulter,
Germany), as previously reported [24]. For lymphocyte analysis, PBMCs were prepared from blood
samples using density gradient sedimentation (Lymphoprep; STEMCELL Technologies, Cologne,
Germany). Trypan blue staining was used for differentiation between viable and nonviable cells, and
showed viability of >90% for all cells used in this study. After gradient separation, cells were stained with
lymphocyte antibody mix for 20 min at 4°C in the dark. Data acquisition was performed in a BD LSRII
flow cytometer or a BD fluorescence-activated cell sorter (FACS) ARIA II (both Becton Dickinson,
Heidelberg, Germany) if cells were sorted. Data was analysed with FlowJo software (TreeStart Inc,
Ashland, OR, USA). Negative thresholds for gating were set according to isotype-labelled controls.
T-cell suppression assay and MDSC co-culture
The T-cell suppression assay and MDSC co-cultures were performed as previously published [19, 25].
Briefly, PBMCs from IPF patients were isolated, stained with CFSE (CellTrace, C34554; ThermoFisher
Scientific, Darmstadt, Germany) and stimulated with recombinant human IL-2 (100 U·mL−1; BD
Pharmingen, San Diego, CA, USA) and OKT3 (1 µg·mL−1; Biolegend, San Diego, CA, USA). PBMCs were
incubated with stimulation media alone or with isolated autologous MDSC. After 4 days, cells were harvested
and stained with anti-CD4-PE or anti-CD8-allophycocyanin (Biolegend). CSFE fluorescence intensity of
each cell type was analysed by flow cytometry. The percentage of proliferation was analysed for CD8+ and
CD4+ cells cultured alone or in conjunction with MDSC. Data were analysed with FlowJo software. After
96 h of incubation, cells were harvested and stained with anti-CD4-PE (BD Pharmingen) and
anti-CD8-allophycocyanin. CFSE fluorescence intensity was analysed by flow cytometry to determine
proliferation of CD4+ and CD8+ T-cells. After 96 h of incubation, cells were harvested and stained with
anti-CD4-PE (BD Pharmingen) and anti-CD8-allophycocyanin. CFSE fluorescence intensity was analysed by
flow cytometry to determine proliferation of CD4+ and CD8+ T-cells.
TABLE 1 Patient demographics and clinical characteristics
Characteristics Control IPF Non-IPF ILD COPD
Subjects 22 69 56 23
Age years 55.4±6.4 68.2±11.1** 62.5±10.4* 58.3±6.4
Sex
Male 11 (50%) 55 (79.7%) 30 (53.5%) 11 (47.8%)






Current 5 (22.7%) 5 (7.2%) 0 1 (4.3%)
Former 6 (27.2%) 40 (57.9%) 26 (46.4%) 22 (95.6%)
Nonsmokers 11 (50%) 24 (34.7%) 30 (53.6%) 0
DLCO % pred 33.8±16.7 32.5±16.3 25.3±18.7
VCmax % pred 61.6±17.8 61.3±19.2 61.1±26.6
Data are presented mean±SD, unless otherwise stated. IPF: idiopathic pulmonary fibrosis; ILD: interstitial
lung disease; COPD: chronic obstructive pulmonary disease; CTD: connective tissue disease; HP:
hypersensitivity pneumonitis; NSIP: nonspecific interstitial pneumonia; DLCO: diffusing capacity of the lung
for carbon monoxide; VCmax: maximum vital capacity. #: subjects with ⩾5 pack-years of cigarette smoking.
*: p<0.05 versus healthy controls; **: p<0.01 versus healthy controls.
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Statistical analysis
Data are presented as scatter plots with mean±SD. Two group comparisons were made using a
non-parametric two-tailed Mann–Whitney U-test, parametric test or paired t-test, when specified. Three
or more group comparisons were made using one-way ANOVA, with the non-parametric Kruskal–Wallis
test followed by Dunnett’s test. Associations between variables were established by linear regression and
Pearson correlation. GraphPad Prism (version 5.0; GraphPad Software, San Diego, CA, USA) was used for
statistical analyses. Significance was defined as p<0.05.
Results
Patient demographics
In total, 170 patients and controls were included in this study (table 1). From those, 69 were diagnosed
with IPF, 56 with non-IPF ILD (connective tissue disease-ILD: n=12, hypersensitivity pneumonitis: n=17;
nonspecific interstitial pneumonia: n=27) and 23 with COPD, and 22 were healthy controls. Patient
demographics are shown in table 1.
MDSC are increased in the peripheral blood of patients with lung fibrosis
Whole blood MDSC (defined as lineageneg/HLA-DRneg/CD33+/CD11b+ cells) were measured and
quantified in freshly drawn blood in all study subjects. Previous reports in several types of cancer [11] or
lung disorders have described human circulating MDSCs as monocytic (CD14+) or granulocytic (CD66b+)
[13]. In order to set a threshold for positive–negative discrimination, a fluorescently labelled isotype was
used as a control for each subject (figure 1a). To exclude definitive differentiated and mature cell
populations, a cocktail with lineage-definitive markers was used and positive cells were excluded (figure
1a). This was followed by exclusion of HLA-DR-positive cells and further gating on CD33 and CD11b
positivity. Two distinct populations were observed: a CD33++/CD11b+, characterised by strong CD14
expression and monocytic morphology; and a CD33+/CD11b+, characterised by strong CD66b expression
and granulocytic morphology (figure 1). We used FACS-sorted monocytic and granulocytic MDSCs to
confirm their morphology using cytospins with Diff-quick staining, as well as co-expression of CD33 and
CD11b by immunofluorescence staining (figure 1b).
Next, we quantified the abundance of MDSCs (as % gated of HLA-DRneg cells) in all subjects. We
observed that the amount of MDSCs was significantly elevated in the peripheral blood of IPF
(30.99±15.61%, p<0.01) and non-IPF ILD patients (31.63±15.61%, p<0.05) when compared with controls
(18.96±8.17%) or COPD (25.63±13.94%, p=NS) (figure 2a). Next, to determine which MDSC phenotype
was prevalent in IPF patients, we quantified the proportion of mo-MDSC (as % gated CD33++CD11b+ cells)
and g-MDSC (as % gated CD33+CD11b+ cells). Interestingly, we observed that the proportion of mo-MDSC
was significantly increased in IPF compared with controls (figure 2b). Inversely, the proportion of g-MDSC
was significantly decreased (figure 2c).
Increased MDSC abundance reflects poor lung function specifically in IPF patients
To elucidate the clinical relevance of increased circulating MDSCs, we analysed whether higher numbers
of MDSCs correlated with physiological parameters that determine disease status, such as lung function.
We observed that, in a cross-sectional analysis, higher numbers of peripheral blood MDSCs inversely
correlated with maximum vital capacity (VCmax % predicted) (p<0.0001, r=−0.48) in IPF. The
MDSC-VCmax correlation remained significant when all patients were pooled together, albeit with a less
stringent correlation coefficient (p=0.0027, r=−0.24) (figure 3). Correlation analysis was also performed
for non-IPF ILD and COPD, but no significant correlation was found for these groups (p=0.5, r=−0.07
and p=0.5, r=−0.14, respectively).
Although our study was not designed as a prospective longitudinal study, a number of patient revisits
occurred in the study period; thus, we were able to analyse the relationship between the change in MDSC
and VCmax over time in the same patients. As depicted in figure 4, 27 patients were assessed by follow-up
analysis (IPF: n=14, non-IPF ILD: n=11, COPD: n=2). While the initial values are included in all patients’
analysis (figure 2), we performed an additional analysis for repeat visits by correlating the delta (Δ) MDSC
with ΔVCmax % predicted (Δ=V2−V1). By using this calculation, we could uncover whether the number
of MDSCs changed with declining lung function over time. When patients were analysed altogether a
nonsignificant weak negative correlation was observed (r=0.09189) (figure 4a). When we analysed only IPF
patients, a strong and significant correlation was observed (r=−0.5773, p=0.0389) (figure 4b).
MDSC from IPF patients effectively suppress T-cell proliferation
To confirm that peripheral blood MDSCs from IPF patients suppressed T-cell proliferation, we isolated
and co-cultured PBMCs with autologous MDSCs, and assessed the suppressive function of MDSC in vitro.
PBMCs were isolated (non-IPF ILD: n=5, IPF: n=4), stained with CFSE and cultured over a period of
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4 days. CD4+ and CD8+ T-cells showed a baseline proliferation of 70.61±18.73% and 83.69±7.68%,
respectively, when cultured alone in stimulation media. When autologous MDSCs were added to these
cultures, at a ratio of 1:4 (T cell:MDSC), CD4+ and CD8+ T-cell proliferation were significantly decreased,
confirming MDSC suppressive functions (figure 5a and b).
Patients with IPF exhibit elevated levels of immunosuppressive lymphocytes
Next, we analysed lymphocyte subtypes in all subjects to test the hypothesis that an MDSC-lymphocyte axis
might contribute to the immunosuppressive network in IPF. We did not observe significant differences in
several T-cell subsets, including T-helper (effector and non-effector) or T-cytotoxic (effector and
non-effector) cells (figure E3). However, a significant decrease in abnormal T-cells (CD3+CD4+CD8+) was
observed in non-IPF ILD (1.36±1.3% versus 3.14±2.8%, p=0.0079) when compared with controls (figure E3).
When we analysed CD4+ CD25+ cells, a population that includes T-reg cells, we observed a significant
increase in IPF (52.96±21%, p=0.0002) and non-IPF ILD (55.78±19.8%, p=0.0002) when compared with
controls (32.8±17.7%) (figure 6a). We performed intracellular FoxP3 staining in lymphocytes of 26 IPF
patients to determine T-reg cell abundance and correlated the percentage of T-reg cells with MDSCs. A
significant positive correlation between T-reg cells and MDSCs was observed (p=0.0484, r=0.3326)

























FIGURE 1 Characterisation of human myeloid-derived suppressor cells (MDSC) in whole blood. Representative dot-plots of whole blood flow
cytometry analysis after red blood cell lysis. a) Cells were stained with a panel of monoclonal antibody and gated on Linneg, HLA-DRneg, CD33+
+CD11b+ and CD33+CD11b+, and further characterised as monocytic (mo-MDSC: CD14+) or granulocytic (g-MDSC: CD66b+), depicted in the
histograms as blue and green, respectively. Gates were based on isotype-stained samples, represented as grey in the histograms. Microscopic
analysis of Diff-quick stained cytospins of fluorescence-activated cell sorter (FACS)-sorted mo-MDSC and g-MDSC confirmed phenotypic
characteristics. b) Immunofluorescence staining of FACS-sorted mo-MDSC (top) and g-MDSC (bottom) are depicted as single channels (CD33 in
green; CD11b in red) and merged channels confirmed the co-expression of MDSC markers. Scale bars=5 µm. SSC: side-scattered light; FSC:
forward-scattered light; HLA-DR: human leukocyte antigen-DR.
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qPCR analysis for a set of four genes that were recently related to T-cell co-stimulatory signals [7].
Importantly, the mRNA transcripts of CD28, ICOS, ITK and LCK were significantly decreased in IPF
patients with high circulating MDSCs when compared with controls (figure 6c).
MDSC are detected in the lungs of IPF patients
To date, tissue-infiltrating MDSCs have been described in several human cancer types, where they have
been shown to differentiate, for example, into immunosuppressive tumour-associated macrophages or
dendritic cells [26, 27]. To determine whether MDSCs are present in the fibrotic lung, we investigated lung
tissue from explants of fibrotic patients (IPF and chronic hypersensitivity pneumonitis) for the presence of
CD33+CD11b+ positive cells. Sequential immunofluorescence stains from fibrotic lung tissues revealed that
CD33+CD11b+ double-positive cells, suggestive of MDSC, are present in collagen 1-positive areas and
neighbouring α-SMA-positive areas in the fibrotic lung parenchyma outside vessels (figure 7).
Discussion
Our study demonstrates, for the first time, an increased abundance of circulating and tissue-infiltrating
MDSCs in patients with IPF and non-IPF ILD. Specifically in IPF, MDSC abundance in the peripheral
blood inversely correlates with lung function. We further detected a suppressive function in IPF MDSCs,
along with an increase in circulating CD4+CD25+ activated T-cells, a correlation between MDSCs and
FoxP3-positive T-reg cells, and a decrease in the transcript levels of CD28, ICOS, ITK and LCK in
PBMCs. In our opinion, these are remarkable observations due to the following reasons. First, these data
strongly support a role for an immunosuppressive environment in the peripheral blood and lungs of IPF
patients. Secondly, the tight correlation of increased MDSCs with decreased lung function suggest that
MDSCs, at least in part, contribute to disease progression in IPF, which is further substantiated by















































FIGURE 2 Increased abundance of myeloid-derived suppressor cells (MDSC) in lung fibrosis. a) Scatter-plot
diagrams from flow cytometry analysis of MDSC counts, as % gated HLA-DRneg cells in 22 healthy controls,
69 idiopathic pulmonary fibrosis (IPF), 56 non-IPF interstitial lung disease (ILD) and 23 chronic obstructive
pulmonary disease (COPD) patients. b) Monocytic (mo)-MDSC as % gated CD33++CD11b+ and c) granulocytic
(g)-MDSC as % gated CD33+CD11b+ cells in 22 controls and 69 IPF patients. For statistical analysis, one-way
ANOVA with the non-parametric Kruskal–Wallis test, followed by Dunnett’s multiple comparison test (a), and
non-parametric two-tailed Mann–Whitney U-test (b, c) was used. *: p<0.05 versus healthy controls; **: p<0.01
versus healthy controls. HLA-DR: human leukocyte antigen-DR.
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abundance and/or function are currently manipulated in cancer trials. Targeting MDSC abundance and/or
function may, therefore, represent an exciting novel treatment approach in IPF. Altogether, these data
reveal that MDSCs are part of an immune-deregulated environment and reflect disease status in IPF.
In recent years, it has become apparent that immune dysregulation is a key contributor to fibrogenesis in a
number of organs. The innate and adaptive immune system can enhance the secretion of pro-fibrotic
a) b)
c) d)































































FIGURE 3 Myeloid-derived suppressor cells (MDSC) abundance inversely correlates with maximum vital
capacity (VCmax) % predicted in idiopathic pulmonary fibrosis (IPF). The percentage of gated MDSC (as %
gated HLA-DRneg cells) was inversely correlated with VCmax, as % predicted values in a) IPF, b) all subjects,
c) non-IPF interstitial lung disease and d) chronic obstructive pulmonary disease. p-values were determined
by t-distribution for Pearson correlation.
a) b)




























FIGURE 4 Follow-up analysis reveals correlation of myeloid-derived suppressor cells (MDSC) abundance with
the disease course of idiopathic pulmonary fibrosis (IPF). Δ % gated MDSC and maximum vital capacity
(VCmax) % predicted was calculated for patients with consecutive visits for a) all diagnosis (n=27) and b) IPF
only (n=14). The ΔVCmax and ΔMDSC, calculated from visit 1 to 2, were correlated. p-values were determined
by t-distribution for Pearson correlation.
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factors that direct the healing/scarring response towards a fibrotic outcome [9]. Historically, harmful
effects of global immunosuppressive therapy in IPF (e.g. by using prednisone and/or azathioprine)
outweighed this possibility, as a randomised controlled trial reported an increased mortality in IPF
patients subjected to anti-inflammatory therapy [28]. Herein, we provide compelling evidence for the
observation that IPF patients exhibit an immunosuppressive network in the peripheral blood and lungs,
driven by MDSCs. Taking this into account, traditional immunosuppressive therapies would, instead,
perpetuate the already dysregulated immune environment and be deleterious for disease.
A growing body of literature supports a role for T-cells in IPF pathogenesis [29]. MARCHAL-SOMMÉ et al. [30]
reported ectopic formation of secondary lymphoid tissue in fibrotic niches of IPF lungs, supporting enhanced
migration and generation of activated T- and B-cell subtypes in IPF. Although several subtypes of activated
T-cells have been associated with progression and outcome in IPF, the literature remains controversial to date.
Recently, GILANI et al. [6] showed that CD4+ T-cells displayed a marked downregulation in the surface
expression of CD28 in IPF, which was associated with worse outcome. The CD4+CD28- T-cells detected in
this study showed a decrease in CD25 and FoxP3 expression. Nonetheless, CD4+CD25+FoxP3+ total numbers
(non-discriminated by CD28) were not reported in this study. Furthermore, KOTSIANIDIS et al. [8] reported
that peripheral blood and BAL T-reg cells (CD4+CD25+FoxP3+) were decreased in IPF. Importantly,
the identification of T-reg subsets in fibrotic conditions of the human lung is more discriminative when
CD4+/CD25+/CD27+ cells are assessed [31]. Recently, Sema7a+/CD4+/CD25+/FoxP3+ cells were found to be
increased in rapidly progressive IPF patients, and adoptive transfer of these cells to transforming growth
factor-β overexpressing mice was sufficient to induce fibrosis [5], corroborating the notion that increased
T-reg cells induce and/or facilitate fibrogenesis in the lung. In other animal models of fibrosis, depletion of
CD4+CD25+FoxP3+ cells by administration of a blocking CD25 antibody switched T-helper 2-driven
responses towards a T-helper 1 kind and attenuated fibrosis development [32].
Importantly, extensive gene expression profiling in the peripheral blood of IPF patients has recently
extended this knowledge. YANG et al. [33] first demonstrated that the peripheral blood transcriptome in
IPF patients varies from normal individuals by documenting that 1428 and 2790 genes were differentially
regulated in mild versus severe IPF, respectively, when compared with controls. Extending this observation,
HERAZO-MAYA et al. [7] showed that gene expression patterns in PBMCs predict outcome in IPF patients.
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FIGURE 5 Myeloid-derived suppressor cells (MDSC) suppress autologous T-cell proliferation in idiopathic pulmonary fibrosis. Representative
histogram of a) CD4+ and b) CD8+ T-cell proliferation, assessed by carboxyfluorescein succinimidyl ester (CFSE) incorporation and measured by
flow cytometry, with medium only (left-hand panels) and co-cultured with autologous MDSC (right-hand panels). Quantification of % proliferation
of c, d) CD4+ and e, f ) CD8+ T-cells alone or in co-culture with autologous MDSC for all patients (n=9) (c, e) or idiopathic pulmonary fibrosis only
(n=4) (d, f ). For statistical analysis paired t-tests were used. **: p<0.01.
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Although these data support an important role for immunosuppression in IPF by elucidating the role of
T-reg cells, another major innate immunosuppressive cell type, MDSC, has not been investigated at all in
lung fibrosis. In the lung, the presence of MDSCs was initially described in advanced nonsmall cell lung
cancer [34], where their presence has been widely explored, both clinically [17] and mechanistically [35].
In cystic fibrosis, MDSCs have been associated with Pseudomonas aeruginosa infections, demonstrating
that this pathogen induced MDSC generation via flagellin [19]. In TB, increased MDSC numbers are
described to suppress T-cell functions [18]. To this extent, KNAUL et al. [36] unravelled a complex role of
MDSCs in murine TB. MDSCs accumulated in TB lungs, acted as phagocytes and provided a cellular
shelter for mycobacteria, which then suppressed T-cell responses and led to increased TB lethality. In
pulmonary hypertension, MDSCs are increased and their levels correlated with increased mean pulmonary
artery pressure [37]. In COPD, recent work demonstrated an effector T-cell dysfunction composed by
T-reg cells, MDSC and PD-1 exhausted effector T-cells [20].
Of note, we did not observe a significant increase in MDSC numbers in COPD patients in our study. This
difference could be due to the fact that KALATHIL et al. [20] investigated an older and more advanced
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FIGURE 6 CD25+ T-cells, FoxP3+ regulatory T-cells (T-reg) and co-stimulatory T-cell signals are dysregulated in
idiopathic pulmonary fibrosis (IPF). a) Scatter-plot diagrams from flow cytometry analysis of CD25+ T-cells (as %
gated CD3+CD4+) in 22 healthy controls, 69 IPF, 56 non-IPF interstitial lung disease (ILD) and 23 chronic
obstructive pulmonary disease (COPD) patients. For statistical analysis, one-way ANOVA was used with the
non-parametric Kruskal–Wallis test, followed by Dunnett’s multiple comparison test. b) Correlation of % FoxP3+
T-reg cells (as % gated CD4+CD25+) and myeloid-derived suppressor cells (MDSC). p-values were determined by
t-distribution for Pearson correlation. c) qPCR analysis of CD28, ICOS, ITK and LCK in peripheral blood
mononuclear cell pellets of healthy controls (n=14) and IPF patients (n=21). Non-parametric two-tailed Mann–
Whitney U-test was used for statistical analysis. *: p<0.05; **: p<0.01; ***: p<0.001.
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COPD population, with worse baseline lung function compared to our cohort. It is also critical to
highlight that, due to the diverse strategies to phenotypically define MDSC, it is difficult to compare
absolute cell numbers across diseases.
Granulocytic MDSCs are described to be the predominant MDSC subtype in malignancies of several organ
systems. Surprisingly, our analysis of MDSC subtypes in IPF revealed that monocytic MDSCs are the
predominant subtype in IPF. PEYVANDI et al. [38] recently demonstrated that modulation of the Fas–FasL
pathway did not increase overall MDSC abundance; however, it skewed the MDSC subtype towards a highly
suppressive monocytic MDSC subtype. It simultaneously increased the number of tumour-associated
macrophages and T-reg cells, and increased tumour growth with decreased survival in a mouse model of
lung cancer [38]. We believe that further studies are necessary to clarify the differential contribution of
MDSC subtypes to lung fibrosis.
Previous reports have shown that ageing affects MDSC abundance, influencing the progression of
age-related pathologies [39]. The age of our IPF population was significantly higher when compared with
controls (mean age 68.2 versus 55.4 years). However, it is important to note the mean age for the young
adult population in the study mentioned above was 32 years, i.e. 20 years younger than our control group.
Therefore, we consider that the effect of age only for our analysis is minimal.
In repeated visits in our study we demonstrated that increased MDSC numbers over time significantly
correlated with the decline in VCmax. This was observed in a greater extent in IPF patients than in
non-IPF ILD or COPD. We reason for this may be due to the fact that IPF exhibits different disease
pathogenesis than non-IPF ILD. Also non-IPF ILD exhibits more variability in its natural history and
treatment responsiveness, which may influence data interpretation.
One of the critical roles of MDSCs is their ability to suppress immune cell function, especially by the




FIGURE 7 CD33+CD11b+ cells are present in fibrotic areas of idiopathic pulmonary fibrosis (IPF) lungs. Representative immunofluorescence of
sequential cuts from paraffin sections of IPF lungs are shown stained for: a) CD33 (red) and CD11b (green), b) CD11b (red) and collagen 1 (green),
and c) CD33 (red) and α-SMA (green). For all, nuclei were counterstained with DAPI (blue). Lower magnifications (left-hand panel) are presented
at 10× (scale bar=50 µm). White squares represent higher magnifications (scale bar=20 µm), depicted as merged images and single channel
images for the red and green channel. CD33+CD11b+ cells are indicated with a white arrow. Sections are representative stains of two IPF patients
and one hypersensitivity pneumonitis patient.
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induction of T-reg cells [26], all of which are pro-fibrotic players [40]. At the tumour site, MDSCs can
differentiate into tumour-associated macrophages [27, 41] or regulatory dendritic cells [42]. Furthermore,
in mouse models of metastatic melanoma and breast cancer, MDSCs were shown to differentiate into
fibrocytes, in a KLF4-dependent manner, to support the establishment of lung metastasis [43]. In a
murine model of renal fibrosis, fibrocytes generated from a subpopulation MDSC under control of CD4+
cells contributed to renal deposition of collagen type I [44]. A population of circulating MDSC-like
fibrocytes was initially reported in metastatic cancer patients by ZHANG et al. [45], which showed
expression of α-SMA, collagen I/V and mediation of angiogenesis. Importantly, circulating fibrocytes
numbers are increased in IPF [46] and non-IPF ILD [47], and have been associated with poor prognosis.
It is therefore important to define the overlap between FACS-defined MDSC and fibrocytes in future
prospective studies.
Ample evidence supports the use of MDSCs as biomarkers for clinical outcomes in cancer patients,
specifically when assessing tumour progression and response to therapy [48]. High percentages of
circulating MDSCs have been shown to predict resistance to anticancer therapies and shorter survival [49].
Further evidence supporting the promotion of tumour growth, differentiation and metastasis by MDSCs is
growing. In diffuse large B-cell lymphoma [50] and melanoma [51], MDSCs are an independent
prognostic factor. In head and neck squamous cell carcinoma, MDSC abundance correlated with cancer
stage [52]. In gastric [53] and renal carcinoma [54], MDSC inhibited T-cell proliferation and correlated
with later stage and shorter overall survival. In breast cancer, MDSCs suppress antitumor immune
responses, and correlate with lymph node metastasis [55]. In addition, sufficient evidence from preclinical
models and clinical testing of multiple cancers types, such as melanoma [56], breast cancer [57], nonsmall
cell lung cancer [58] or metastatic kidney cancer [59], demonstrated that targeting and decreasing MDSC
abundance increased the tumour’s sensitivity to chemotherapy. Accordingly, novel therapeutic strategies in
the above-mentioned diseases aim to eliminate, deactivate or skew MDSC number and/or function [26],
and it is probably suitable to explore these interventions in IPF.
IPF has been considered as a cancer-like disorder, due to the activation of common pathogenic pathways
and shared mechanisms (e.g. expansion of tissue-resident cells, activation of pro-proliferative signalling
pathways) that are finally reflected in poor responses to medical treatment and clinical prognosis.
Importantly, MDSC abundance in IPF and many cancer types might further support the available data in
overlapping mechanism between these two conditions.
In conclusion, our study demonstrates, for the first time, the accumulation of MDSCs in peripheral blood
and tissue of IPF patients. MDSCs inversely correlated with lung function, reflecting more advanced
disease in IPF patients with high MDSC. These findings might explain dysregulated T-cell responses in
IPF. Elevated MDSCs might cause a blunted immune response, which also might be an explanatory link
for the increased incidence and burden of lung cancer in IPF. Controlling the expansion and accumulation
of MDSCs or blocking their suppressive functions represents promising novel approaches to be used as a
therapeutic strategy in IPF patients.
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ABSTRACT Fibrotic lung diseases involve subject–environment interactions, together with dysregulated
homeostatic processes, impaired DNA repair and distorted immune functions. Systems medicine-based
approaches are used to analyse diseases in a holistic manner, by integrating systems biology platforms
along with clinical parameters, for the purpose of understanding disease origin, progression, exacerbation
and remission.
Interstitial lung diseases (ILDs) refer to a heterogeneous group of complex fibrotic diseases. The increase
of systems medicine-based approaches in the understanding of ILDs provides exceptional advantages by
improving diagnostics, unravelling phenotypical differences, and stratifying patient populations by
predictable outcomes and personalised treatments. This review discusses the state-of-the-art contributions
of systems medicine-based approaches in ILDs over the past 5 years.
Introduction
Interstitial lung diseases (ILDs) are fibrosing diseases, characterised by a reversible or nonreversible limitation
in the gas exchange capacity of the lung, induced by known or unknown causes. This occurs as a secondary
effect to the excessive accumulation of cells from distinct sources (e.g. mesenchymal, epithelial and
inflammatory), wound healing products and extracellular matrix (ECM) in the lung interstitium. ILDs refer
to a large group of diseases with a high mortality index, overlapping clinical features, unpredictable clinical
progression and no available curative therapies, as is the case for idiopathic pulmonary fibrosis (IPF) [1, 2].
Systems biology is a biology-based interdisciplinary area that studies complex interactions within biological
systems, using a holistic approach to biological research. Driven by high-throughput “omic” technologies, it
enables multiscale and insightful overviews of cells, organisms and populations. Systems medicine integrates
systems biology into modelling of pathological mechanisms, along with clinical parameters. Dynamic
analysis between clinical and omics-generated data through bioinformatic and computational tools helps to
dissect altered pathways, and to understand disease establishment, progression and remission [3].
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SYSTEMS MEDICINE IN ILD
The application of systems medicine to ILDs seeks to analyse their heterogeneity in a comprehensive
manner, with the purpose of identifying biomarkers and genetic factors that improve disease understanding
from the physio-pathological and clinical perspectives. While there are many key studies that have increased
our knowledge of IPF and other ILDs, this article concisely focuses on omic-related studies, which
contributed to the field during the past 5 years. Contributions published prior to this time frame were
comprehensively reviewed in 2012 by HERAZO-MAYA and KAMINSKI [4].
Systems medicine and ILDs
With scientific advancement and accessibility at reasonable costs, the widespread use of high-throughput
omic technologies has increased greatly over the last decade. This phenomenon has had a major impact on
our understanding of multiple diseases, where omic-generated data have led to a personalised approach,
decreasing mortality and improving survival, e.g. in the case of HER2 (human epidermal growth factor
receptor type 2)-positive breast cancer patients or EGFR (epidermal growth factor receptor)-mutated
patients. Omic-driven personalised medicine has the potential to allow individualised treatment selection,
determined by specific characteristics of the patient and disease.
There are overlapping similarities among ILDs subtypes, complicating the precise diagnosis and
representing a daily challenge in clinical practice. The available treatment options are limited, increasing the
need for molecular fingerprinting of patient populations. Thus, this complex and heterogeneous group of
diseases requires the integrated approach of systems medicine to clearly discriminate and better understand
them. We consider that advances in multiplex approaches allow us to glimpse critical players in these
biological systems (figure 1). However, confirmatory testing of individual interactions is critical to
demonstrate the importance at the molecular, cellular and organism level. A combination of holistic and
traditional reductionist approaches will thus be needed for further understanding this multifaceted disease
process.
Systems medicine in IPF
IPF has the worst prognosis of all ILDs, with a median survival of 3–5 years after diagnosis and no
curative treatment available [2, 5]. Distinct clinical phenotypes with different patterns of survival have
being described in IPF [5]. Therefore, systems medicine represents a new era for IPF. Interesting
biomarkers have been discovered using omic analysis (table 1) and the challenge now is to establish them
in routine clinical practice. Currently, only clinical and physiological changes are used to characterise
disease progression.
Genomics and transcriptomics
Advances in genomic techniques have allowed high-throughput analysis and discovery of gene
deregulation in IPF [6]. In particular, genetic studies have contributed to a better understanding of IPF,
e.g. the expression of MUC5B (mucin 5B) and TOLLIP (Toll-interacting protein) [7–9]. Polymorphism in
the promoter region of MUC5B (rs35705950) is associated with a higher likelihood of IPF development,
although patients carrying this allele present a milder disease course and improved survival [7]. MUC5B
was found expressed in areas of microscopic honeycombing and honeycomb cysts [8]. To date, the precise
role of MUC5B in the pathophysiology of IPF is unclear.
Furthermore, variants in TOLLIP have also been linked to susceptibility and treatment responses in IPF.
Single nucleotide polymorphisms within TOLLIP (rs5743890/rs3750920) are associated with increased
mortality risk (rs5743890) and better response to N-acetylcysteine treatment (rs3750920) in IPF patients
[9, 10]. Similarly, DSP (desmoplakin) variance (rs2076295) is associated with increased risk of IPF.
MUC5B and DSP expression in the lung, especially in the airway epithelium, indicates the contribution of
the aberrant epithelium in IPF [11].
Most IPF cases are sporadic. However, genetic variations also include an autosomal dominance pattern of
inheritance, leading to familial pulmonary fibrosis. Several studies showed a strong relationship between
familial IPF and telomerase mutations and their shortening. Recently, a prospective study performed
genetic evaluations of IPF patients and affected relatives, and confirmed a strong relationship between
familial IPF and telomerase mutations and shortening [12, 13]. Several studies have reported that familial
IPF is associated with variances of the genes TERT (telomerase reverse transcriptase), TERC (telomerase
RNA component), DKC1 (dyskerin pseudouridine synthase 1), TINF2 (TERF1 interacting nuclear factor 2),
RTEL1 (regulator of telomere elongation helicase 1) and PARN (poly(A)-specific RNase) [12, 13]. Familial
IPF also presents mutations within surfactant protein-encoding genes SFTPA2 (surfactant protein A2) and
SFTPC (surfactant protein C), and ABCA3 (ATP-binding cassette subfamily A member 3) [12, 14].
MicroRNAs (miRNAs) are small noncoding RNAs involved in the regulation of gene and protein
expression, thus altering cellular phenotypes. IPF patients display downregulation of miRNA levels in
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members of the let-7, mir-29 and mir-30 families, and upregulation in members of the mir-155 and
mir-21 families, which modulate biological pathways and modify the IPF phenotype [15]. Altered
expression of let-7 family members leads to changes in epithelial–mesenchymal transition in lung
epithelial cells and inhibition of mir-21 modulates fibrosis [15]. mir-29 is also being explored as a
potential target for IPF therapy as it decreases collagen expression in fibrotic lungs [16].
Moreover, IPF shares features with other chronic lung diseases, such as chronic obstructive pulmonary
disease (COPD), where the molecular mechanism of lung injury leads to airway fibrosis. KUSKO et al. [17]
revealed a shared mRNA–miRNA transcriptional network between IPF and COPD. Specifically, upregulation
of mir-96 in both diseases may control part of the shared disease gene expression network. KUSKO et al. [17]
describe overexpression of mir-96 as a key novel regulator of p53 expression in both epithelial cells and
fibroblasts, which modulates the expression of genes related to the “emphysema–IPF” gene network [17].
Currently, miRNA therapy is being explored as a therapeutic option in diverse fibrotic conditions.
Cell-based RNA genomics can also provide an insight into disease features and targetable molecules. In
line with the study by KUSKO et al. [17], single-cell RNA sequencing analysis of IPF and control lungs
identified the cross-talk of four distinct lung epithelial cell subtypes (alveolar type 2, goblet, basal and
indeterminate) [18]. XU et al. [18] showed that cells isolated from IPF patients express genes associated
with activation of canonical transforming growth factor (TGF)-β, HIPPO/YAP, PI3K/AKT, p53 and WNT
signalling cascades, which are activated in an integrated network [18]. Myofibroblast differentiation and
massive ECM deposition are both ideal targetable phenomena in fibrotic diseases [19]. PARKER et al. [19]
used fibroblasts to explore at the RNA level how proteins present in the ECM of acellular lungs can
provoke a feedback loop to normal living cells exposed to an aberrant environment. The results suggest
that characterisation of lung proteins, specifically the lung fibrotic ECM, will help to not only determine
its composition, but also to define targetable molecules for advanced stages of fibrosis [19].
Advances in genomic technologies show an exciting time ahead, where analysis of the genetic makeup of






























FIGURE 1 Systems medicine-based approaches in interstitial lung diseases seek to analyse biological products (e.g. RNA, DNA, proteins,
metabolites, microbiome, etc.) and, through massive data generation and integration with clinical features, help to identify biomarkers that can
predict disease phenotypes. OTU: operational taxonomic unit; MUC5B: mucin 5B; ICAM-1: intracellular adhesion molecule-1; MMP-7:
metalloproteinase-7; TOLLIP: Toll-interacting protein; TERT: telomerase reverse transcriptase.
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clinical genotyping and biomarker testing is essential for future patient stratification and personalised
treatment.
Proteomics
As a substantial part of systems medicine, proteomics covers information on protein abundance, variation
and modification, including their partners and networks, in order to explain cellular processes. Given the
impact of aberrant biological processes in IPF, proteomics analysis provides global protein quantification
as a critical tool to identify disease-driving molecules and potential targets. The most universal and
powerful method for global protein measurement is mass spectrometry, which uses liquid chromatography
together with high-resolution tandem mass spectrometry to identify and quantify peptides at a large scale.
These techniques, together with bioinformatic tools, contribute to a better understanding of protein
biochemistry, nature and interaction.
It is possible that many of the proteins dysregulated in IPF may not cross the lung endothelial barrier or
become diluted out by more abundant constituents, thus being undetectable in plasma [20]. Based on this
concept, initial studies with proteomics in IPF have been primarily performed in bronchoalveolar lavage
fluid (BALF). Osteopontin has been a more strongly validated marker increased in the BALF of IPF
patients. Other targets have also been associated with disease, e.g. the CC chemokine ligand CCL24,
surfactant protein A2, and transcriptional factors NF-κB, peroxisome proliferator-activated receptor-γ and
c-Myc [20–22]. Recently, it was reported from proteomics analysis of fibroblast surface fractions that
platelet-derived growth factor receptor (PDGFR)-α expression was altered by pro-fibrotic TGF-β in lung




Genomics MUC5B [7, 8]
TOLLIP [9]
let-7, mir-30, mir-155, mir-21 [15]
mir-29 [15, 16]
Proteomics CCL24, surfactant protein A2, NF-κB, peroxisome
proliferator-activated receptor-γ
[20–22]
Platelet-derived growth factor receptor-α [23]






Microbiome Staphylococcus OTU 1348 [30–32]




CD28, inducible T-cell costimulator, lymphocyte-specific protein
tyrosine kinase, interleukin-2 inducible T-cell kinase
[34, 35]
Neoepitopes BGM, C1M, C3M, C5M, C6M, CRPM [36]
Plasma B-lymphocyte stimulating factor, B-cells [37]
Myeloid-derived suppressor cells [38]
Familial IPF
Genomics TERT, TERC, DKC1, TINF2, RTEL1, PARN [12, 13]
SFTPA2, SFTPC, ABCA3 [12, 14]
Non-IPF ILDs
Genomics Telomere length [43]
RTEL1 [44]
DPP9, DSP, FAM13A, IVD, DISP2, OBFC1, ATP11A, MUC2 [45]
ADAMTS4, ADAMTS9, AGER, HIF1A, SERPINE2, SELE, RTKN2, PI15 [48]
IPF: idiopathic pulmonary fibrosis; OTU: operational taxonomic unit. See main text for further details of
gene symbols.
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fibroblasts from IPF patients [23]. The authors suggest a potential cross-talk between two critical signalling
pathways in fibrosis, i.e. TGF-β/PDGFR-α, which affects myofibroblast differentiation in the context of IPF
[23], currently insufficiently targeted by approved therapies.
In an iTRAQ (isobaric tag for relative and absolute quantitation)-based proteomics study, NIU et al. [24]
identified a set of proteins in the serum of IPF patients. The identified targets were related to the protein
activation cascade, regulation of response to wounding and extracellular components (see table 1).
Unfortunately, no correlation with clinical parameters was performed. Recently, using a 1129-analyte
SOMAmer (slow off-rate modified aptamer) array in IPF plasma, a six-analyte index predicted better
progression-free survival in IPF. Specifically, high levels of ficolin-2, cathepsin-S, legumain and soluble
vascular endothelial growth factor receptor-2, and low levels of inducible T-cell costimulator (ICOS) or
trypsin-3 were associated with IPF progression [25]. The use of this index should be further validated in
independent cohorts for general applicability.
Metabolomics
Metabolites are the second product of metabolic reactions catalysed by enzymes that naturally occur in the
cells, complementing gene and protein expression [26]. Metabolic changes of the lung are involved in IPF
pathogenesis, as reported by KANG et al. [27]. IPF presented 25 metabolite signatures, which indicated
alteration in metabolic pathways of ATP degradation, glycolysis, glutathione biosynthesis and ornithine
aminotransferase pathways [27]. Interestingly, ornithine has a negative correlation with forced vital capacity
(FVC), suggesting the potential role of ornithine in IPF pathophysiology [27]. Moreover, lactic acid levels
and lactate dehydrogenase (LDH)-5 levels were elevated in IPF lungs when compared with controls [28].
Increased levels of LDH-5 activate the TGF-β pathway, inducing myofibroblast differentiation [28].
Microbiome
The human microbiota consists of 10–100 trillion symbiotic microbial cells in a single individual; however,
little is known about the contribution of the microbiome to health and disease. Recently, it was reported that
IPF patients have higher bacterial load in BALF when compared with controls and the increased bacterial
load identifies patients with more rapidly progressive disease [29]. Interestingly, MOLYNEAUX et al. [29] found
bacterial burden to be independent of MUC5B genotype, suggesting a direct connection between host
immunity and bacterial load [29]. In addition, it has been described in the COMET cohort that microbial
signatures of Staphylococcus and Streptococcus help predict IPF progression [30]. Disease progression was
significantly associated with increased abundance of two specific strains of Staphylococcus and Streptococcus.
The study determined two operational taxonomic units (OTUs) associated with disease progression:
Staphylococcus OTU 1348 and Streptococcus OTU 1345 [30]. This altered microbiome persists over time,
which may implicate bacterial communities localised in the lower airways as persistent stimuli for repetitive
alveolar injury in IPF [31]. IPF patients from the COMET cohort showed interactions between the host
microbiome and progression-free survival [32]. Downregulation of the immune response was associated with
changes in the abundance of Staphylococcus OTU 1348, which correlated with alterations in circulating
leukocyte phenotypes, expression of several Toll-like receptors and fibroblast responsiveness [32].
Peripheral blood phenotyping
In the past, the role of the immune system in IPF has been controversial. However, increasing
contributions indicate multiple alterations in the immune compartment of IPF patients, raising interest in
the field. The peripheral blood compartment provides an easily accessible liquid biopsy, highly practical to
study molecules and cell types as potential biomarkers. IPF patients have an increase in circulating
biomarkers, e.g. CCL18, metalloproteinase (MMP)-7 and soluble intracellular adhesion molecule-1. To
date, MMP-7 is the most validated biomarker to adopt clinically for diagnosis and prognostic evaluation of
IPF [33]. Recently, several studies have validated the immunosuppressive environment present in the
peripheral blood of IPF patients, showing that the gene expression of CD28, ICOS, lymphocyte-specific
protein tyrosine kinase and interleukin-2 inducible T-cell kinase can predict outcome in IPF [34, 35].
In PROFILE, the largest IPF biomarker cohort studied globally, JENKINS et al. [36] showed changes in
serum concentrations of proteolytically cleaved protein fragments/neopitopes. Levels of fragmented
proteins generated by MMP activity and collagen synthesis in the serum of IPF patients were associated
with IPF progression, as well as survival rate [36]. Immune cell type dysfunction has also been implicated
in IPF. Abnormal B-cells and B-cell stimulator factor are often present in IPF patients, and are highly
associated with disease manifestations and patient outcome [37]. Furthermore, myeloid-derived suppressor
cells were described as a potent biomarker for IPF, where increased numbers of myeloid-derived
suppressor cells measured in the blood of IPF patients correlated with lung function in cross-sectional and
longitudinal analysis [38].
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Omics in non-IPF ILDs
Non-IPF ILDs are defined by a large group of diseases classified by know causes or associations, e.g.
idiopathic interstitial pneumonias (IIPs), granulomatous and other forms of ILDs [39]. The majority of
non-IPF ILDs are idiopathic nonspecific interstitial pneumonia (NSIP), hypersensitivity pneumonitis,
connective tissue disease-associated ILD and sarcoidosis. These diffuse parenchymal lung diseases affect
the interstitium of the lung, distort pulmonary architecture and alter the gas exchange ability of the lung.
ILDs can have associated causes, or not, but once scarring occurs, it is irreversible. The heterogeneity of
non-IPF ILDs is extremely complex, with multiple common features and a high overlap in clinical,
radiological and pathological patterns. Therefore, diagnosis requires a multidisciplinary approach and, in
some cases, surgical lung biopsy, thus increasing mortality risk [40]. This highlights the need for
integrated systems biology platforms to determine the molecular fingerprinting that improves diagnostic
accuracy and provides novel targetable molecules.
KIM et al. [41] used integrative clustering analysis to integrate multi-omics data and propose an integrative
phenotyping framework for identification of disease subtypes. Well-characterised clinical data, mRNA and
miRNA profiles were integrated and visualised. Applying this method, clusters of homogeneous disease
presentations and intermediate disease characteristics were identified. Validation of this open-access tool
with other datasets is needed to support wide clinical usage. The integration of multi-omics data (e.g.
proteomic, metabolomic, genomic and clinical data) provides a holistic integration of disease-related
pathways at multiple levels, giving a futuristic perspective of understanding disease [41]. Using machine
learning approaches with high-dimensional transcriptional data, a genomic signature could cluster ILD
patients (IIP, NSIP, hypersensitivity pneumonitis and sarcoidosis) with a specificity of 92% (95% CI
81–100%) and a sensitivity of 82% (95% CI 64–95%) for microarray analysis, and a specificity of 95%
(95% CI 84–100) and a sensitivity of 59% (95% CI 35–82%) for RNA sequencing. This study continues to
support the need for better and less invasive diagnostic methods for ILDs patients [42]. Additionally,
telomere length has been shown to be relevant in different ILDs. Telomeres are shorter in ILDs patients
when compared with healthy controls, and even shorter in IPF when compared with other IIPs and
sarcoidosis [43]. Moreover, a rare loss-of-function variant in RTEL1 was found in peripheral blood
mononuclear cells in one out of 25 families, representing a genetic predisposition for familiar interstitial
pneumonia [44]. FINGERLIN et al. [45] identified 10 risk loci for fibrotic IIP (fIIP), e.g. DPP9 (dipeptidyl
peptidase 9), DSP, FAM13A (family with sequence similarity 13 member A), IVD (isovaleryl-CoA
dehydrogenase), DISP2 (dispatched RND transporter family member 2), OBFC1 (oligonucleotide/
oligosaccharide-binding fold-containing protein 1), ATP11A (ATPase phospholipid transporting 11A) and
MUC2 (mucin 2), by genome-wide association studies. Furthermore, by imputing the data of genome-wide
genotypes and conducting RNA sequencing studies, they identified new fIIP risk loci in lung tissue.
Fibrotic lung tissue showed a deregulation in the human leukocyte antigen region of chromosome 6
(rs7887), involving and reaffirming the role of an immune deregulation in fibrotic ILDs [46].
Using the two-dimensional DIGE (difference in gel electrophoresis) technique and MALDI-TOF-MS
(matrix assisted laser desorption ionisation-time of flight mass spectrometry), KORFEI et al. [47] sought
differences between IPF and fibrotic NSIP, reporting that differences in expression of only a few proteins
exist between these two entities. Although it is currently a limited and low-sensitivity proteome measuring
technique, the authors interestingly reported that intracellular clearance of reactive oxygen species and
carbonyl proteins seems to be enhanced in NSIP, due to enhanced expression of antioxidant acting
proteins, which may explain the better outcome and survival in patients with NSIP [47].
Assessing the relationship between changes in lung function parameters and gene expression is a helpful
method to identify clinically relevant molecules implicated in disease. STEELE et al. [48] used tissue gene
expression profiling of IIPs to analyse differences and similarities among several IIPs, estimating the
relationship between gene regulation and disease progression (using percentage predicted values for FVC
and diffusing capacity of the lung for carbon monoxide). Some previously reported fibrotic targets were
confirmed, e.g. ADAMTS4 (ADAM metallopeptidase with thrombospondin type 1 motif 4), ADAMTS9
(ADAM metallopeptidase with thrombospondin type 1 motif 9), AGER (advanced glycosylation
end-product specific receptor), HIF1A (hypoxia inducible factor 1 α subunit), SERPINE2 (serpin family E
member 2) and SELE (selectin E), and novel candidates were identified, e.g. RTKN2 (rhotekin 2) and PI15
(peptidase inhibitor 15). Gene expression changes in those targets were significantly associated with lung
function decline in moderate and severe IIP patients [48].
Conclusions
The pathobiology of pulmonary fibrosis involves adaptive and maladaptive pathways that work on multiple
biological levels to disturb organ function. A comprehensive understanding of this complex interaction
requires the integration of multiple data types: from DNA sequence variations to transcriptomics to
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proteomics and ultimately phenomics, notwithstanding data obtained by classical physiology and
pathology across different tissue and cell types. The speed of progress in science and technology applied to
medicine in recent years has allowed several endotypes of diseases to be defined: from systems
medicine-based approaches, leading to detection of specific targets that subclassify disease, to the
possibility of offering personalised treatment, as is the case for EGFR in lung cancer.
Genome editing technologies, such as the CRISPR (clustered regularly interspaced palindromic
repeat)-associated protein Cas9 (CRISPR-Cas9) system, provide hope that the discovery of critical gene
regulators of disease can be applied to gene correction, such that CRISPR-Cas9-mediated gene correction
could theoretically be offered for personalised treatments [49, 50]. Recently, XIE et al. [51] showed that
glycolytic reprogramming is critical to lung myofibroblast differentiation and pulmonary fibrosis. Using
CRISPR-Cas9 tools, inhibition of glycolysis was achieved by gene disruption of PFKFB3
(6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, a critical glycolytic enzyme). This example raises
our hope that gene editing can be used for individualised therapeutics.
A combination of holistic and traditional reductionist experimental approaches will thus be required for
the understanding of this multifaceted disease process. Notably, there are far more omics-related studies
investigating IPF than other ILDs. Thus, community efforts must be invested in comprehensively
characterising all ILDs, to learn more precisely about their common and distinctive features, and translate
this gain of knowledge into more refined treatment options and better patient care than currently
practised.
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